1
|
Chen YC, Lin YH, Lu CT, Yii CY, Chen PC, Yong SB. Correspondence to "Oral immunotherapy in alpha-gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?". Allergy 2024; 79:1073-1074. [PMID: 38340015 DOI: 10.1111/all.16048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Accepted: 01/31/2024] [Indexed: 02/12/2024]
Affiliation(s)
- Yi-Chen Chen
- School of Medicine, China Medical University, Taichung, Taiwan
| | - Yu-Hsi Lin
- School of Chinese Medicine, China Medical University, Taichung, Taiwan
| | - Chi-Tung Lu
- School of Medicine, China Medical University, Taichung, Taiwan
| | - Chin-Yuan Yii
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Landseed International Hospital, Taoyuan, Taiwan
- Department of Biomedical Sciences and Engineering, National Central University, Taoyuan, Taiwan
| | - Pei-Chi Chen
- Center for Allergy, Immunology, and Microbiome (A.I.M.), China Medical University Hospital, Taichung, Taiwan
| | - Su-Boon Yong
- Center for Allergy, Immunology, and Microbiome (A.I.M.), China Medical University Hospital, Taichung, Taiwan
- Department of Allergy, Immunology, and Rheumatology (AIR), China Medical University Children's Hospital, Taichung, Taiwan
- Department of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
| |
Collapse
|
2
|
Hung SHW, Yeh PH, Huang TC, Huang SY, Wu IC, Liu CH, Lin YH, Chien PR, Huang FC, Ho YN, Kuo CH, Hwang HH, Chiang EPI, Huang CC. A cyclic dipeptide for salinity stress alleviation and the trophic flexibility of endophyte provide insights into saltmarsh plant-microbe interactions. ISME Commun 2024; 4:ycae041. [PMID: 38707842 PMCID: PMC11070113 DOI: 10.1093/ismeco/ycae041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 02/23/2024] [Accepted: 03/20/2024] [Indexed: 05/07/2024]
Abstract
In response to climate change, the nature of endophytes and their applications in sustainable agriculture have attracted the attention of academics and agro-industries. This work focused on the endophytic halophiles of the endangered Taiwanese salt marsh plant, Bolboschoenus planiculmis, and evaluated the functions of these isolates through in planta salinity stress alleviation assay using Arabidopsis. The endophytic strain Priestia megaterium BP01R2, which can promote plant growth and salinity tolerance, was further characterized through multi-omics approaches. The transcriptomics results suggested that BP01R2 could function by tuning hormone signal transduction, energy-producing metabolism, multiple stress responses, etc. In addition, the cyclodipeptide cyclo(L-Ala-Gly), which was identified by metabolomics analysis, was confirmed to contribute to the alleviation of salinity stress in stressed plants via exogenous supplementation. In this study, we used multi-omics approaches to investigate the genomics, metabolomics, and tropisms of endophytes, as well as the transcriptomics of plants in response to the endophyte. The results revealed the potential molecular mechanisms underlying the occurrence of biostimulant-based plant-endophyte symbioses with possible application in sustainable agriculture.
Collapse
Affiliation(s)
- Shih-Hsun Walter Hung
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
- Institute of Plant and Microbial Biology, Academia Sinica, Taipei 115201, Taiwan
- Advanced Plant and Food Crop Biotechnology Center, National Chung Hsing University, Taichung 402202, Taiwan
| | - Pin-Hsien Yeh
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
| | - Tsai-Ching Huang
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
| | - Shao-Yu Huang
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
| | - I-Chen Wu
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
| | - Chia-Ho Liu
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
| | - Yu-Hsi Lin
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
| | - Pei-Ru Chien
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
| | - Fan-Chen Huang
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
| | - Ying-Ning Ho
- Institute of Marine Biology, College of Life Science, National Taiwan Ocean University, Keelung 202301, Taiwan
- Centre of Excellence for the Oceans, National Taiwan Ocean University, Keelung 202301, Taiwan
- Taiwan Ocean Genome Center, National Taiwan Ocean University, Keelung 202301, Taiwan
| | - Chih-Horng Kuo
- Institute of Plant and Microbial Biology, Academia Sinica, Taipei 115201, Taiwan
- Biotechnology Center, National Chung Hsing University, Taichung 402202, Taiwan
| | - Hau-Hsuan Hwang
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
- Advanced Plant and Food Crop Biotechnology Center, National Chung Hsing University, Taichung 402202, Taiwan
- Innovation and Development Center of Sustainable Agriculture, National Chung Hsing University, Taichung 402202, Taiwan
| | - En-Pei Isabel Chiang
- Advanced Plant and Food Crop Biotechnology Center, National Chung Hsing University, Taichung 402202, Taiwan
- Innovation and Development Center of Sustainable Agriculture, National Chung Hsing University, Taichung 402202, Taiwan
- Department of Food Science and Biotechnology, National Chung Hsing University, Taichung 402202, Taiwan
| | - Chieh-Chen Huang
- Department of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan
- Advanced Plant and Food Crop Biotechnology Center, National Chung Hsing University, Taichung 402202, Taiwan
- Innovation and Development Center of Sustainable Agriculture, National Chung Hsing University, Taichung 402202, Taiwan
| |
Collapse
|
3
|
An LL, Zhao DF, Hou RF, Guan HH, Yan H, Lin YH, Tong CR, Wu T, Liu SY. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:911-916. [PMID: 38185520 PMCID: PMC10753260 DOI: 10.3760/cma.j.issn.0253-2727.2023.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Indexed: 01/09/2024]
Abstract
Objective: To observe the treatment response of a two-dose regimen of inotuzumab ozogamicin (inotuzumab), a monoclonal antibody targeting CD22, for patients with heavily treated relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), including those failed or relapsed after chimeric antigen receptor (CAR) -T-cell therapy. Methods: Pediatric and adult patients who received two doses of inotuzumab and who were evaluated after inotuzumab treatment were included. Antibody infusions were performed between March 2020 and September 2022. All patients expressed CD22 antigen as detected by flow cytometry (>80% leukemic cells displaying CD22) before treatment. For adults, the maximum dosage per administration was 1 mg (with a total of two administrations). For children, the maximum dosage per administration was 0.85 mg/m(2) (no more than 1 mg/dose; total of two administrations). The total dosage administered to each patient was less than the standard dosage of 1.8 mg/m(2). Results: Twenty-one patients with R/R B-ALL were included, including five children (<18 years old) and sixteen adults. Seventeen patients presented with 5.0% -99.0% leukemic blasts in the bone marrow/peripheral blood or with extramedullary disease, and four patients were minimal residual disease (MRD) -positive. Fourteen patients underwent both CD19 and CD22 CAR-T-cell therapy, four underwent CD19 CAR-T-cell therapy, and three underwent blinatumomab therapy. Eleven patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). After inotuzumab treatment, 14 of 21 patients (66.7% ) achieved a complete response (CR, one was MRD-positive CR), and all four MRD-positive patients turned MRD-negative. Four of six patients who failed recent CD22 CAR-T-cell therapy achieved a CR after subsequent inotuzumab treatment. Seven patients (33.3% ) demonstrated no response. Grade 1-3 hepatotoxicity occurred in five patients (23.8% ), one child with no response experienced hepatic veno-occlusive disease (HVOD) during salvage transplantation and recovered completely. Conclusion: For patients with heavily treated R/R B-ALL, including those who had undergone allo-HSCT and CD19/CD22 CAR-T-cell therapy, the two-dose regimen of inotuzumab resulted in a CR rate of 66.7%, and the frequency of hepatotoxicity and HVOD was low.
Collapse
Affiliation(s)
- L L An
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| | - D F Zhao
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| | - R F Hou
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| | - H H Guan
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| | - H Yan
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| | - Y H Lin
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| | - C R Tong
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| | - T Wu
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| | - S Y Liu
- Beijing GoBroad Boren Hospital, Beijing 100070, China
| |
Collapse
|
4
|
Khadka S, Lin YH, Ackroyd J, Chen YA, Sheng Y, Qian W, Guo S, Chen Y, Behr E, Barekatain Y, Uddin N, Arthur K, Yan V, Hsu WH, Chang Q, Poral A, Tran T, Chaurasia S, Georgiou DK, Asara JM, Barthel FP, Millward SW, DePinho RA, Muller FL. Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism. bioRxiv 2023:2023.05.07.539744. [PMID: 37214825 PMCID: PMC10197573 DOI: 10.1101/2023.05.07.539744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Tumor angiogenesis is a cancer hallmark, and its therapeutic inhibition has provided meaningful, albeit limited, clinical benefit. While anti-angiogenesis inhibitors deprive the tumor of oxygen and essential nutrients, cancer cells activate metabolic adaptations to diminish therapeutic response. Despite these adaptations, angiogenesis inhibition incurs extensive metabolic stress, prompting us to consider such metabolic stress as an induced vulnerability to therapies targeting cancer metabolism. Metabolomic profiling of angiogenesis-inhibited intracranial xenografts showed universal decrease in tricarboxylic acid cycle intermediates, corroborating a state of anaplerotic nutrient deficit or stress. Accordingly, we show strong synergy between angiogenesis inhibitors (Avastin, Tivozanib) and inhibitors of glycolysis or oxidative phosphorylation through exacerbation of anaplerotic nutrient stress in intracranial orthotopic xenografted gliomas. Our findings were recapitulated in GBM xenografts that do not have genetically predisposed metabolic vulnerabilities at baseline. Thus, our findings cement the central importance of the tricarboxylic acid cycle as the nexus of metabolic vulnerabilities and suggest clinical path hypothesis combining angiogenesis inhibitors with pharmacological cancer interventions targeting tumor metabolism for GBM tumors.
Collapse
Affiliation(s)
- Sunada Khadka
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Yu-Hsi Lin
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jeffrey Ackroyd
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Yi-An Chen
- Cancer and Cell Biology Division, The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA
| | - Yanghui Sheng
- Crown Bioscience Inc., Suzhou Industrial Park, 218 Xinghu Rd, Jiangsu, China
| | - Wubin Qian
- Crown Bioscience Inc., Suzhou Industrial Park, 218 Xinghu Rd, Jiangsu, China
| | - Sheng Guo
- Crown Bioscience Inc., Suzhou Industrial Park, 218 Xinghu Rd, Jiangsu, China
| | - Yining Chen
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Eliot Behr
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yasaman Barekatain
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Nasir Uddin
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kenisha Arthur
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Victoria Yan
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Wen-Hao Hsu
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Qing Chang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Anton Poral
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Theresa Tran
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Surendra Chaurasia
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Dimitra K Georgiou
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John M Asara
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Floris P Barthel
- Cancer and Cell Biology Division, The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA
| | - Steve W Millward
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ronald A DePinho
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Florian L Muller
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
- Present address: Sporos Bioventures, Houston, TX, USA
| |
Collapse
|
5
|
Lin YH, Azraai M, Miura D, Rodrigues T, Nadurata V. Incidence of Radiotherapy Induced Cardiac Implantable Electronic Devices Malfunction: Australian-Based Observation Study. Int J Radiat Oncol Biol Phys 2023; 117:e408. [PMID: 37785356 DOI: 10.1016/j.ijrobp.2023.06.1550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To assess the incidence rate of cardiac implantable electronic devices (CIED) malfunction with radiotherapy (RT) and identify factors resulting in CIED malfunction. The working hypothesis is that CIED malfunction is associated with higher photon beam energy, treatment anatomical location, device type and dose to device. MATERIALS/METHODS This retrospective review involved 441 patients with CIED treated with RT. Clinical information, RT (prescription, dose to device, beam energy, anatomical regions treated etc.) and CIED details (type, manufacturer, and device malfunction) were collected from electronic medical records. RESULTS A total of 344 patients (78%) had a permanent pacemaker (PPM), 44 patients (10%) had implantable cardioverter defibrillator (ICD), 44 patients (10%) had CRT-defibrillator (CRT-D) and 9 (2%) had cardiac resynchronization therapy-pacing (CRT-P). The median prescribed dose was 36 Gy (IQR 1.8-80 Gy). 17 out of 441 patients (3.9%) experienced an CIED malfunction event. This group had a higher prescribed median dose of 42.5 Gy (IQR 20-77 Gy) and beam energy of 14 MV (12-18 MV). None of the malfunctions resulted in clinical symptoms. Median dose to CIED was 0.28 Gy (IQR 0-3.3). No patents received dose to device ≥2 Gy. Using logistic regression, the predictors of CIED malfunction were photon beam energy use ≥10 MV (OR 5.73; 95% CI, 1.58-10.76), anatomical location of RT above the diaphragm (OR 5.2, 95% CI, 1.82-15.2), and having an ICD (OR 4.6, 95% CI, 0.75-10.2). CONCLUSION We have demonstrated that photon beam energies ≥10 MV, RT to above the diaphragm and ICD devices are significantly associated with CIED malfunction. The recorded CIED malfunctions in this study were minor malfunctions which did not result in any clinical symptoms. Stringent adherence to the local institution's CIED treatment guidelines, utilization of safety measures and careful choice of beam energy are recommended to minimize risk of symptomatic CIED malfunctions.
Collapse
Affiliation(s)
- Y H Lin
- Alfred Health, Melbourne, VIC, Australia; Peter McCallum Cancer Centre, Melbourne, VIC, Australia
| | - M Azraai
- Bendigo Health, Bendigo, VIC, Australia
| | - D Miura
- Bendigo Health, Bendigo, VIC, Australia
| | - T Rodrigues
- Monash University, Melbourne, VIC, Australia
| | | |
Collapse
|
6
|
Yan VC, Pham CD, Ballato ES, Yang KL, Khadka S, Barektain Y, Shrestha P, Tran T, Poral AH, Washington M, Raghavan S, Czako B, Pisaneschi F, Lin YH, Satani N, Hammoudi N, Ackroyd JJ, Georgiou DK, Millward SW, Muller FL. Abstract 3097: Prodrugs of a 1-hydroxy-2-oxopiperidin-3-yl phosphonate enolase inhibitor for the treatment of ENO1-deleted cancers. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-3097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Cancers harboring homozygous deletion of the glycolytic enzyme enolase 1 (ENO1) are selectively vulnerable to inhibition of the paralogous isoform, enolase 2 (ENO2). We previously identified and characterized a competitive, small molecule phosphonate inhibitor of ENO2, 1-hydroxy-2-oxopiperidin-3-yl phosphonate (HEX), and its lipophilic bis-ester prodrug (POMHEX) in an ENO1-deleted intracranial orthotopic xenograft model of glioblastoma. Treatment with either HEX (150 mg/kg IV/IP) or POMHEX (20 mg/kg IV/IP) yielded tumor regression even after drug discontinuation. However, due to the poor pharmacokinetics of esterase-labile POMHEX, we synthesized a library of novel phosphonate prodrugs with distinct mechanisms of bioactivation and assessed their potency in D423 (ENO1-/-) cells. By conducting a prodrug structure activity relationship (SAR) study, we found that phosphonoamidate esters were efficiently bioactivated in ENO1-deleted glioma cells, while canonical McGuigan (ProTide) prodrugs were not. Other strategies, including salicylic alcohol (cycloSal) and lipid prodrugs of HEX, exhibited low micromolar IC50 values in ENO1-deleted glioma cells and improved stability in human serum over POMHEX. En route, we developed a novel class of aliphatic amine/ester prodrugs that can be broadly applied to efficiently deliver phosph(on)ate pharmacophores in cells. The activity of select prodrugs was also probed using the NCI-60 cell line screen, supporting its use to examine the relationship between prodrugs and cell line-dependent bioactivation. In sum, we have developed a novel class of phosph(on)ate prodrugs that is efficiently bioactivated in cells in vitro. Our prodrug SAR study disputes the common notion that ProTides are universally advantageous promoieties on phosph(on)ate pharmacophores and we provide mechanistic rationale for this observation with HEX. Finally, we show that the cycloSal prodrug yields efficient intracellular delivery of HEX in vitro, with a mechanism of bioactivation consistent with the GBM microenvironment, making this promoiety promising for further evaluation in vivo.
Citation Format: Victoria C. Yan, Cong-Dat Pham, Elliot S. Ballato, Kristine L. Yang, Sunada Khadka, Yasaman Barektain, Prakriti Shrestha, Theresa Tran, Anton H. Poral, Mykia Washington, Sudhir Raghavan, Barbara Czako, Federica Pisaneschi, Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, Jeffrey J. Ackroyd, Dimitra K. Georgiou, Steven W. Millward, Florian L. Muller. Prodrugs of a 1-hydroxy-2-oxopiperidin-3-yl phosphonate enolase inhibitor for the treatment of ENO1-deleted cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3097.
Collapse
Affiliation(s)
| | - Cong-Dat Pham
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Sunada Khadka
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Theresa Tran
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | - Anton H. Poral
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Barbara Czako
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Yu-Hsi Lin
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | - Nikunj Satani
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | - Naima Hammoudi
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | |
Collapse
|
7
|
Allega A, Anderson MR, Andringa S, Antunes J, Askins M, Auty DJ, Bacon A, Barros N, Barão F, Bayes R, Beier EW, Bezerra TS, Bialek A, Biller SD, Blucher E, Caden E, Callaghan EJ, Cheng S, Chen M, Cleveland B, Cookman D, Corning J, Cox MA, Dehghani R, Deloye J, Deluce C, Depatie MM, Dittmer J, Dixon KH, Di Lodovico F, Falk E, Fatemighomi N, Ford R, Frankiewicz K, Gaur A, González-Reina OI, Gooding D, Grant C, Grove J, Hallin AL, Hallman D, Heintzelman WJ, Helmer RL, Hu J, Hunt-Stokes R, Hussain SMA, Inácio AS, Jillings CJ, Kaluzienski S, Kaptanoglu T, Khaghani P, Khan H, Klein JR, Kormos LL, Krar B, Kraus C, Krauss CB, Kroupová T, Lam I, Land BJ, Lawson I, Lebanowski L, Lee J, Lefebvre C, Lidgard J, Lin YH, Lozza V, Luo M, Maio A, Manecki S, Maneira J, Martin RD, McCauley N, McDonald AB, Mills C, Morton-Blake I, Naugle S, Nolan LJ, O'Keeffe HM, Orebi Gann GD, Page J, Parker W, Paton J, Peeters SJM, Pickard L, Ravi P, Reichold A, Riccetto S, Richardson R, Rigan M, Rose J, Rosero R, Rumleskie J, Semenec I, Skensved P, Smiley M, Svoboda R, Tam B, Tseng J, Turner E, Valder S, Virtue CJ, Vázquez-Jáuregui E, Wang J, Ward M, Wilson JR, Wilson JD, Wright A, Yanez JP, Yang S, Yeh M, Yu S, Zhang Y, Zuber K, Zummo A. Evidence of Antineutrinos from Distant Reactors Using Pure Water at SNO. Phys Rev Lett 2023; 130:091801. [PMID: 36930908 DOI: 10.1103/physrevlett.130.091801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 12/14/2022] [Accepted: 01/20/2023] [Indexed: 06/18/2023]
Abstract
The SNO+ Collaboration reports the first evidence of reactor antineutrinos in a Cherenkov detector. The nearest nuclear reactors are located 240 km away in Ontario, Canada. This analysis uses events with energies lower than in any previous analysis with a large water Cherenkov detector. Two analytical methods are used to distinguish reactor antineutrinos from background events in 190 days of data and yield consistent evidence for antineutrinos with a combined significance of 3.5σ.
Collapse
Affiliation(s)
- A Allega
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - M R Anderson
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Andringa
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
| | - J Antunes
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
- Universidade de Lisboa, Instituto Superior Técnico (IST), Departamento de Física, Avenida Rovisco Pais, 1049-001, Lisboa, Portugal
| | - M Askins
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720-8153, USA
| | - D J Auty
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
| | - A Bacon
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - N Barros
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
- Universidade de Lisboa, Faculdade de Ciéncias (FCUL), Departamento de Física, Campo Grande, Edifício C8, 1749-016, Lisboa, Portugal
| | - F Barão
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
- Universidade de Lisboa, Instituto Superior Técnico (IST), Departamento de Física, Avenida Rovisco Pais, 1049-001, Lisboa, Portugal
| | - R Bayes
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - E W Beier
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - T S Bezerra
- Physics & Astronomy, University of Sussex, Pevensey II, Falmer, Brighton, BN1 9QH, United Kingdom
| | - A Bialek
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - S D Biller
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - E Blucher
- The Enrico Fermi Institute and Department of Physics, The University of Chicago, Chicago, Illinois 60637, USA
| | - E Caden
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - E J Callaghan
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720-8153, USA
| | - S Cheng
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - M Chen
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - B Cleveland
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - D Cookman
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - J Corning
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - M A Cox
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
- Department of Physics, University of Liverpool, Liverpool L69 3BX, United Kingdom
| | - R Dehghani
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - J Deloye
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - C Deluce
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - M M Depatie
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - J Dittmer
- Technische Universität Dresden, Institut für Kern und Teilchenphysik, Zellescher Weg 19, Dresden 01069, Germany
| | - K H Dixon
- Department of Physics, King's College London, Strand Building, Strand, London WC2R 2LS, United Kingdom
| | - F Di Lodovico
- Department of Physics, King's College London, Strand Building, Strand, London WC2R 2LS, United Kingdom
| | - E Falk
- Physics & Astronomy, University of Sussex, Pevensey II, Falmer, Brighton, BN1 9QH, United Kingdom
| | - N Fatemighomi
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - R Ford
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - K Frankiewicz
- Department of Physics, Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215, USA
| | - A Gaur
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
| | - O I González-Reina
- Universidad Nacional Autónoma de México (UNAM), Instituto de Física, Apartado Postal 20-364, México D.F. 01000, México
| | - D Gooding
- Department of Physics, Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215, USA
| | - C Grant
- Department of Physics, Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215, USA
| | - J Grove
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - A L Hallin
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
| | - D Hallman
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - W J Heintzelman
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - R L Helmer
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - J Hu
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
| | - R Hunt-Stokes
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - S M A Hussain
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - A S Inácio
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
- Universidade de Lisboa, Faculdade de Ciéncias (FCUL), Departamento de Física, Campo Grande, Edifício C8, 1749-016, Lisboa, Portugal
| | - C J Jillings
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - S Kaluzienski
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - T Kaptanoglu
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720-8153, USA
| | - P Khaghani
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - H Khan
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - J R Klein
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - L L Kormos
- Physics Department, Lancaster University, Lancaster LA1 4YB, United Kingdom
| | - B Krar
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Kraus
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - C B Krauss
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
| | - T Kroupová
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - I Lam
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - B J Land
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - I Lawson
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - L Lebanowski
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720-8153, USA
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - J Lee
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Lefebvre
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - J Lidgard
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - Y H Lin
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - V Lozza
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
- Universidade de Lisboa, Faculdade de Ciéncias (FCUL), Departamento de Física, Campo Grande, Edifício C8, 1749-016, Lisboa, Portugal
| | - M Luo
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - A Maio
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
- Universidade de Lisboa, Faculdade de Ciéncias (FCUL), Departamento de Física, Campo Grande, Edifício C8, 1749-016, Lisboa, Portugal
| | - S Manecki
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - J Maneira
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Avenida Professor Gama Pinto, 2, 1649-003, Lisboa, Portugal
- Universidade de Lisboa, Faculdade de Ciéncias (FCUL), Departamento de Física, Campo Grande, Edifício C8, 1749-016, Lisboa, Portugal
| | - R D Martin
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - N McCauley
- Department of Physics, University of Liverpool, Liverpool L69 3BX, United Kingdom
| | - A B McDonald
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Mills
- Physics & Astronomy, University of Sussex, Pevensey II, Falmer, Brighton, BN1 9QH, United Kingdom
| | - I Morton-Blake
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - S Naugle
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| | - L J Nolan
- School of Physics and Astronomy, Queen Mary University of London, 327 Mile End Road, London E1 4NS, United Kingdom
| | - H M O'Keeffe
- Physics Department, Lancaster University, Lancaster LA1 4YB, United Kingdom
| | - G D Orebi Gann
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720-8153, USA
| | - J Page
- Physics & Astronomy, University of Sussex, Pevensey II, Falmer, Brighton, BN1 9QH, United Kingdom
| | - W Parker
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - J Paton
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - S J M Peeters
- Physics & Astronomy, University of Sussex, Pevensey II, Falmer, Brighton, BN1 9QH, United Kingdom
| | - L Pickard
- University of California, Davis, 1 Shields Avenue, Davis, California 95616, USA
| | - P Ravi
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - A Reichold
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - S Riccetto
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - R Richardson
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - M Rigan
- Physics & Astronomy, University of Sussex, Pevensey II, Falmer, Brighton, BN1 9QH, United Kingdom
| | - J Rose
- Department of Physics, University of Liverpool, Liverpool L69 3BX, United Kingdom
| | - R Rosero
- Chemistry Department, Brookhaven National Laboratory, Building 555, P.O. Box 5000, Upton, New York 11973-500, USA
| | - J Rumleskie
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - I Semenec
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - P Skensved
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - M Smiley
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720-8153, USA
| | - R Svoboda
- University of California, Davis, 1 Shields Avenue, Davis, California 95616, USA
| | - B Tam
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - J Tseng
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - E Turner
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - S Valder
- Physics & Astronomy, University of Sussex, Pevensey II, Falmer, Brighton, BN1 9QH, United Kingdom
| | - C J Virtue
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - E Vázquez-Jáuregui
- Universidad Nacional Autónoma de México (UNAM), Instituto de Física, Apartado Postal 20-364, México D.F. 01000, México
| | - J Wang
- University of Oxford, The Denys Wilkinson Building, Keble Road, Oxford, OX1 3RH, United Kingdom
| | - M Ward
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - J R Wilson
- Department of Physics, King's College London, Strand Building, Strand, London WC2R 2LS, United Kingdom
| | - J D Wilson
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
| | - A Wright
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - J P Yanez
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
| | - S Yang
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
| | - M Yeh
- Chemistry Department, Brookhaven National Laboratory, Building 555, P.O. Box 5000, Upton, New York 11973-500, USA
| | - S Yu
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - Y Zhang
- Department of Physics, University of Alberta, 4-181 CCIS, Edmonton, Alberta T6G 2E1, Canada
- Research Center for Particle Science and Technology, Institute of Frontier and Interdisciplinary Science, Shandong University, Qingdao 266237, Shandong, China
- Key Laboratory of Particle Physics and Particle Irradiation of Ministry of Education, Shandong University, Qingdao 266237, Shandong, China
| | - K Zuber
- Technische Universität Dresden, Institut für Kern und Teilchenphysik, Zellescher Weg 19, Dresden 01069, Germany
- MTA Atomki, 4001 Debrecen, Hungary
| | - A Zummo
- Department of Physics & Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104-6396, USA
| |
Collapse
|
8
|
Yan VC, Barekatain Y, Lin YH, Satani N, Hammoudi N, Arthur K, Georgiou DK, Jiang Y, Sun Y, Marszalek JR, Millward SW, Muller FL. Comparative Pharmacology of a Bis-Pivaloyloxymethyl Phosphonate Prodrug Inhibitor of Enolase after Oral and Parenteral Administration. ACS Pharmacol Transl Sci 2023; 6:245-252. [PMID: 36798479 PMCID: PMC9926520 DOI: 10.1021/acsptsci.2c00216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Indexed: 01/08/2023]
Abstract
Metabolically labile prodrugs can experience stark differences in catabolism incurred by the chosen route of administration. This is especially true for phosph(on)ate prodrugs, in which successive promoiety removal transforms a lipophilic molecule into increasingly polar compounds. We previously described a phosphonate inhibitor of enolase (HEX) and its bis-pivaloyloxymethyl ester prodrug (POMHEX) capable of eliciting strong tumor regression in a murine model of enolase 1 (ENO1)-deleted glioblastoma following parenteral administration. Here, we characterize the pharmacokinetics and pharmacodynamics of these enolase inhibitors in vitro and in vivo after oral and parenteral administration. In support of the historical function of lipophilic prodrugs, the bis-POM prodrug significantly improves cell permeability of and rapid hydrolysis to the parent phosphonate, resulting in rapid intracellular loading of peripheral blood mononuclear cells in vitro and in vivo. We observe the influence of intracellular trapping in vivo on divergent pharmacokinetic profiles of POMHEX and its metabolites after oral and parenteral administration. This is a clear demonstration of the tissue reservoir effect hypothesized to explain phosph(on)ate prodrug pharmacokinetics but has heretofore not been explicitly demonstrated.
Collapse
Affiliation(s)
- Victoria C. Yan
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Yasaman Barekatain
- Department
of Cancer Biology, University of Texas MD
Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Yu-Hsi Lin
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Nikunj Satani
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Naima Hammoudi
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Kenisha Arthur
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Dimitra K. Georgiou
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Yongying Jiang
- Institute
of Applied Cancer Science, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Yuting Sun
- Institute
of Applied Cancer Science, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Joseph R. Marszalek
- Center
for Co-Clinical Trials, University of Texas
MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Steven W. Millward
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| | - Florian L. Muller
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States
| |
Collapse
|
9
|
Zhang W, Auguste A, Liao X, Walterskirchen C, Bauer K, Lin YH, Yang L, Sayedian F, Fabits M, Bergmann M, Binder C, Corrales L, Vogt AB, Hudson LJ, Barnes MP, Bisht A, Giragossian C, Voynov V, Adam PJ, Hipp S. A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clin Cancer Res 2022; 28:5190-5201. [PMID: 36166004 PMCID: PMC9713360 DOI: 10.1158/1078-0432.ccr-22-2108] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 08/22/2022] [Accepted: 09/22/2022] [Indexed: 01/24/2023]
Abstract
PURPOSE Advanced-stage gastrointestinal cancers represent a high unmet need requiring new effective therapies. We investigated the antitumor activity of a novel T cell-engaging antibody (B7-H6/CD3 ITE) targeting B7-H6, a tumor-associated antigen that is expressed in gastrointestinal tumors. EXPERIMENTAL DESIGN Membrane proteomics and IHC analysis identified B7-H6 as a tumor-associated antigen in gastrointestinal tumor tissues with no to very little expression in normal tissues. The antitumor activity and mode of action of B7-H6/CD3 ITE was evaluated in in vitro coculture assays, in humanized mouse tumor models, and in colorectal cancer precision cut tumor slice cultures. RESULTS B7-H6 expression was detected in 98% of colorectal cancer, 77% of gastric cancer, and 63% of pancreatic cancer tissue samples. B7-H6/CD3 ITE-mediated redirection of T cells toward B7-H6-positive tumor cells resulted in B7-H6-dependent lysis of tumor cells, activation and proliferation of T cells, and cytokine secretion in in vitro coculture assays, and infiltration of T cells into tumor tissues associated with tumor regression in in vivo colorectal cancer models. In primary patient-derived colorectal cancer precision-cut tumor slice cultures, treatment with B7-H6/CD3 ITE elicited cytokine secretion by endogenous tumor-infiltrating immune cells. Combination with anti-PD-1 further enhanced the activity of the B7-H6/CD3 ITE. CONCLUSION These data highlight the potential of the B7-H6/CD3 ITE to induce T cell-redirected lysis of tumor cells and recruitment of T cells into noninflamed tumor tissues, leading to antitumor activity in in vitro, in vivo, and human tumor slice cultures, which supports further evaluation in a clinical study.
Collapse
Affiliation(s)
- Wei Zhang
- Boehringer Ingelheim Pharmaceuticals, Inc., Cancer Immunology & Immune Modulation, Ridgefield, Connecticut
| | - Aurélie Auguste
- Boehringer Ingelheim Pharma, GmbH & Co KG, Translational Medicine and Clinical Pharmacology, Biberach an der Riß, Germany
| | - Xiaoyun Liao
- Boehringer Ingelheim Pharmaceuticals, Inc., Oncology Translational Science, Ridgefield, Connecticut
| | | | - Kathrin Bauer
- Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria
| | - Yu-Hsi Lin
- Boehringer Ingelheim Pharmaceuticals, Inc., Cancer Immunology & Immune Modulation, Ridgefield, Connecticut
| | - Ling Yang
- Boehringer Ingelheim Pharmaceuticals, Inc., Cancer Immunology & Immune Modulation, Ridgefield, Connecticut
| | | | - Markus Fabits
- Medical University of Vienna, Division of Visceral Surgery, Department of General Surgery and Comprehensive Cancer Center, Vienna, Austria
| | - Michael Bergmann
- Medical University of Vienna, Division of Visceral Surgery, Department of General Surgery and Comprehensive Cancer Center, Vienna, Austria
| | - Carina Binder
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - Leticia Corrales
- Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria
| | - Anne B. Vogt
- Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria
| | | | | | - Arnima Bisht
- Oxford BioTherapeutics, Inc., San Jose, California
| | - Craig Giragossian
- Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, Connecticut
| | - Vladimir Voynov
- Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, Connecticut
| | - Paul J. Adam
- Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria
| | - Susanne Hipp
- Boehringer Ingelheim Pharmaceuticals, Inc., Cancer Immunology & Immune Modulation, Ridgefield, Connecticut.,Boehringer Ingelheim Pharmaceuticals, Inc., Translational Medicine and Clinical Pharmacology, Ridgefield, Connecticut.,Corresponding Author: Susanne Hipp, Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368. Phone: 203-798-4567; E-mail:
| |
Collapse
|
10
|
Yan VC, Pham CD, Ballato ES, Yang KL, Arthur K, Khadka S, Barekatain Y, Shrestha P, Tran T, Poral AH, Washington M, Raghavan S, Czako B, Pisaneschi F, Lin YH, Satani N, Hammoudi N, Ackroyd JJ, Georgiou DK, Millward SW, Muller FL. Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers. J Med Chem 2022; 65:13813-13832. [PMID: 36251833 PMCID: PMC9620261 DOI: 10.1021/acs.jmedchem.2c01039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Cancers harboring homozygous deletion of the glycolytic enzyme enolase 1 (ENO1) are selectively vulnerable to inhibition of the paralogous isoform, enolase 2 (ENO2). A previous work described the sustained tumor regression activities of a substrate-competitive phosphonate inhibitor of ENO2, 1-hydroxy-2-oxopiperidin-3-yl phosphonate (HEX) (5), and its bis-pivaloyoxymethyl prodrug, POMHEX (6), in an ENO1-deleted intracranial orthotopic xenograft model of glioblastoma [Nature Metabolism 2020, 2, 1423-1426]. Due to poor pharmacokinetics of bis-ester prodrugs, this study was undertaken to identify potential non-esterase prodrugs for further development. Whereas phosphonoamidate esters were efficiently bioactivated in ENO1-deleted glioma cells, McGuigan prodrugs were not. Other strategies, including cycloSal and lipid prodrugs of 5, exhibited low micromolar IC50 values in ENO1-deleted glioma cells and improved stability in human serum over 6. The activity of select prodrugs was also probed using the NCI-60 cell line screen, supporting its use to examine the relationship between prodrugs and cell line-dependent bioactivation.
Collapse
Affiliation(s)
- Victoria C. Yan
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States,. Twitter: @victoriacyanide
| | - Cong-Dat Pham
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Elliot S. Ballato
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Kristine L. Yang
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Kenisha Arthur
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Sunada Khadka
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States,Department
of Cancer Biology, University of Texas MD
Anderson Cancer Center, Houston, Texas 77054, United States
| | - Yasaman Barekatain
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States,Department
of Cancer Biology, University of Texas MD
Anderson Cancer Center, Houston, Texas 77054, United States
| | - Prakriti Shrestha
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Theresa Tran
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Anton H. Poral
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Mykia Washington
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Sudhir Raghavan
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Barbara Czako
- Institute
of Applied Cancer Science, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Federica Pisaneschi
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Yu-Hsi Lin
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Nikunj Satani
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Naima Hammoudi
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Jeffrey J. Ackroyd
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Dimitra K. Georgiou
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Steven W. Millward
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| | - Florian L. Muller
- Department
of Cancer Systems Imaging, University of
Texas MD Anderson Cancer Center, Houston, Texas 77054, United States
| |
Collapse
|
11
|
Lin YH, Zhou Z. [Cardiovascular biomarkers improve precise risk assessment for cardiovascular diseases]. Zhonghua Yi Xue Za Zhi 2022; 102:2731-2733. [PMID: 36124345 DOI: 10.3760/cma.j.cn112137-20220726-01626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Cardiovascular diseases (CVD) is an urgent threat to Chinese. It is of primary importance to assess risk for cardiovascular diseases. However, there are some limitations about traditional tools for CVD risk assessment. Recently, numbers of clinical trials demonstrated that CVD risk assessments based on cardiovascular biomarkers would significantly improve sensitivity and specificity of prediction. The comment review the limitations of traditional tools for CVD risk assessment, the application value of novel tools and advances of cardiovascular biomarkers in CVD prediction. It is benefit for precise stratification and management of general population during risk stage. Archieving the strategic goal of"Healthy China"would be promising soon.
Collapse
Affiliation(s)
- Y H Lin
- Center of Laboratory Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences, No.167, Beilishi Rd, XiCheng District, Beijing 100037, China
| | - Z Zhou
- Center of Laboratory Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences, No.167, Beilishi Rd, XiCheng District, Beijing 100037, China
| |
Collapse
|
12
|
Wang XL, Lin YH. [A statistical measurement of diseases recorded in The Quarterly Reports of the Ophthalmic Hospital at Canton]. Zhonghua Yi Shi Za Zhi 2022; 52:235-240. [PMID: 36008313 DOI: 10.3760/cma.j.cn112155-20211206-00138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
The Quarterly Reports of the Ophthalmic Hospital at Canton written by Rev. Peter Parker, an American protestant missionary in China, were serialised in The Chinese Repository from 1836 to 1850. Each report provided the number of patients treated in the corresponding period and described in detail the treatment of diseases which were difficult to deal with. However, due to historical conditions, these reports were inconsistent in terms of the disease classification standards, let alone the statistical deficiencies. This paper aims to regroup the diseases recorded in the 15 reports according to the classification from the eleventh to fifteenth report and recount the patient number of each disease systematically in different periods, with reliable historical data to support such relevant studies as the history of the Ophthalmic Hospital at Canton and the introduction of Western Medicine into China and the development of International Classification of Diseases.
Collapse
Affiliation(s)
- X L Wang
- School of Finance Mathematics & Statistics, Guangdong University of Finance,Guangzhou 510521, China
| | - Y H Lin
- School of Interpreting & Translation Studies,Guangdong University of Foreign Studies, Guangzhou 510555, China
| |
Collapse
|
13
|
Khadka S, Lin YH, Ackroyd J, Arthur K, Barekatain Y, Poral A, Tran T, Behr E, Chen Y, Georgiou D, Depinho R, Muller F. Abstract 3208: Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Angiogenesis inhibition has become a mainstay of oncology despite having fallen short of its early promise. As originally envisioned, angiogenesis inhibition would cut off the blood supply, deprive tumor cells of key nutrients, leading to their demise. In practice, while there is evidence that tumors under angiogenesis treatment do in fact exhibit some degree of metabolic stress, this is stress is not sufficient to induce significant cancer cell death. We posit that the full potential of angiogenesis inhibition can be realized by the combination of angiogenesis inhibition with emerging tumor metabolism targeting therapies. Because tumors under angiogenesis inhibition are already in a state of nutrient stress, the effects of metabolically targeted therapies such as amino acid depletion (e.g. asparginase, methionine restriction), inhibitors of stress adaption (AMPK and GCN2 inhibitors) or energy metabolism (e.g. IACS-010759, Metformin, POMHEX) stand to dramatically increase in potency whilst remaining selective for (angiogenic) tumor versus (non-angiogenic) normal tissue. Here, we provide proof-of-principal for this thesis. First, we performed metabolomic profiling of angiogenesis-inhibited tumors, which corroborates a state of nutrient stress in angiogenesis-inhibited tumors. Second, we demonstrate dramatic anti-neoplastic synergy (effectively curing of xenografted tumor-bearing mice, irrespective of initial tumor size), without enhanced adverse toxicities, between the anti-VEGFA antibody Avastin and enolase inhibitor HEX. The same results were recapitulated with the VEGFR inhibitor Tivozanib and HEX and the enolase inhibitor could be substituted with the Oxphos inhibitor IACS-010759, with similar effects. The synergy was observed in a broad range of tumor types, even those without clear genetic susceptibilities. Together, these results suggest that angiogenesis inhibitors synergize broadly with cancer therapies targeting metabolism, allowing the realization of the full potential of these previously disappointing drugs. Our results warrant systematic combination clinical trials between angiogenesis inhibitors and established, as well as emerging anti-metabolic cancer therapies.
Citation Format: Sunada Khadka, Yu-Hsi Lin, Jeffery Ackroyd, Kenisha Arthur, Yasaman Barekatain, Anton Poral, Theresa Tran, Eliot Behr, Yining Chen, Dimitra Georgiou, Ronald Depinho, Florian Muller. Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3208.
Collapse
|
14
|
Lin YH, Yap EP, Sivakumar G, Tee NGZ, Ramachondra CJA, Hausenloy DJ. Cardiac myosin inhibitor, mavacamten, improves myocardial relaxation in mouse HFpEF model. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Medical Research Council (NMRC)
Background / Introduction
There are currently no treatments for directly improving diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF). Improving myocardial relaxation via manipulating sarcomere function has great potential to unveil novel targets for treating HFpEF. Mavacamten, a small molecule inhibitor of myosin ATPase, has been developed through drug screening as a treatment for hypertrophic cardiomyopathy (HCM), and it is currently being tested in HFpEF patients. Interestingly, emerging evidence suggests that mavacamten may not only modulate contractility but may also modulate myocardial relaxation.
Purpose
The aim of this study was to investigate whether mavacamten directly modulates sarcomere mechanical properties to improve myocardial relaxation in a mouse HFpEF model.
Methods
Eight to ten weeks old adult male C57Bl/6 mice were fed with (1) standard diet or (2) high-fat diet (HFD) + L-NAME to induce HFpEF (n=10 mice/group). Cardiac function was assessed by transthoracic two-dimensional echocardiography at baseline and after 15 weeks. Mouse myofibrils (n=10-15 per animals) were obtained from control and HFpEF mice using a triton X-100-based skinning method. The contractile function of the sarcomere with or without the presence of mavacamten were investigated using a myofibril mechanical system. General myofibril mechanical parameters measured included resting and maximal tension (RT, FMAX, mN/mm2), rate constant of tension development (kACT, S-1), duration of linear relaxation phase (tLIN, mSec) and rate constant of linear and exponential phase relaxation (linear and exponential kREL, S-1). Furthermore, force production as a function of the bathing Ca2+ concentration (pCa 4.5-9.0) was measured to determine the Ca2+ sensitivity of the myofibrils.
Results
As previously reported, C57Bl/6 mice fed with HFD + L-NAME developed cardiac hypertrophy, diastolic dysfunction, exercise intolerance despite having preserved systolic function at 15 weeks. Mechanical analysis showed myofibrils isolated from HFpEF mice has mildly reduced force generation, significantly higher stiffness and elevated Ca2+ sensitivity, compared with control animals. Ex vivo treatment of mavacamten completely normalised Ca2+ sensitivity of the myofibrils from HFpEF animals. Interestingly, mavacamten treatment further accelerated the rate of linear phase relaxation (linear kREL).
Conclusion
This is the first study to characterise in detail the mechanical properties of myofibrils in a mouse HFpEF model. We demonstrated myosin ATPase inhibition using mavacamten could normalise elevated Ca2+ sensitivity as well as facilitate relaxation kinetics at the sarcomere level in HFpEF. These findings position mavacamten to be a potential therapeutic intervention for improving diastolic function in patients with HFpEF.
Collapse
Affiliation(s)
- YH Lin
- Duke-NUS Graduate Medical School Singapore , Singapore , Singapore
| | - EP Yap
- Duke-NUS Graduate Medical School Singapore , Singapore , Singapore
| | - G Sivakumar
- University College of London , London , United Kingdom of Great Britain & Northern Ireland
| | - NGZ Tee
- National Heart Centre Singapore , Singapore , Singapore
| | | | - DJ Hausenloy
- Duke-NUS Graduate Medical School Singapore , Singapore , Singapore
| |
Collapse
|
15
|
Pellegrinelli V, Rodriguez-Cuenca S, Rouault C, Figueroa-Juarez E, Schilbert H, Virtue S, Moreno-Navarrete JM, Bidault G, Vázquez-Borrego MC, Dias AR, Pucker B, Dale M, Campbell M, Carobbio S, Lin YH, Vacca M, Aron-Wisnewsky J, Mora S, Masiero MM, Emmanouilidou A, Mukhopadhyay S, Dougan G, den Hoed M, Loos RJF, Fernández-Real JM, Chiarugi D, Clément K, Vidal-Puig A. Dysregulation of macrophage PEPD in obesity determines adipose tissue fibro-inflammation and insulin resistance. Nat Metab 2022; 4:476-494. [PMID: 35478031 DOI: 10.1038/s42255-022-00561-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Accepted: 03/18/2022] [Indexed: 02/02/2023]
Abstract
Resulting from impaired collagen turnover, fibrosis is a hallmark of adipose tissue (AT) dysfunction and obesity-associated insulin resistance (IR). Prolidase, also known as peptidase D (PEPD), plays a vital role in collagen turnover by degrading proline-containing dipeptides but its specific functional relevance in AT is unknown. Here we show that in human and mouse obesity, PEPD expression and activity decrease in AT, and PEPD is released into the systemic circulation, which promotes fibrosis and AT IR. Loss of the enzymatic function of PEPD by genetic ablation or pharmacological inhibition causes AT fibrosis in mice. In addition to its intracellular enzymatic role, secreted extracellular PEPD protein enhances macrophage and adipocyte fibro-inflammatory responses via EGFR signalling, thereby promoting AT fibrosis and IR. We further show that decreased prolidase activity is coupled with increased systemic levels of PEPD that act as a pathogenic trigger of AT fibrosis and IR. Thus, PEPD produced by macrophages might serve as a biomarker of AT fibro-inflammation and could represent a therapeutic target for AT fibrosis and obesity-associated IR and type 2 diabetes.
Collapse
Affiliation(s)
- V Pellegrinelli
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK.
| | - S Rodriguez-Cuenca
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
- Cambridge University Nanjing Centre of Technology and Innovation, Nanjing, P. R. China
| | - C Rouault
- Sorbonne University, INSERM, NutriOmique Research Unit, Paris, France
| | - E Figueroa-Juarez
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
| | - H Schilbert
- Genetics and Genomics of Plants, Centre for Biotechnology (CeBiTec) & Faculty of Biology, Bielefeld University, Bielefeld, Germany
| | - S Virtue
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
| | - J M Moreno-Navarrete
- Department of Diabetes, Endocrinology and Nutrition, Girona Biomedical Research Institute (IDIBGI), University Hospital of Girona Dr Josep Trueta, Girona, Spain
- Department of Medicine, University of Girona, Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Institut of Salud Carlos III, Madrid, Spain
| | - G Bidault
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
| | - M C Vázquez-Borrego
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
- Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain
| | - A R Dias
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
| | - B Pucker
- Genetics and Genomics of Plants, Centre for Biotechnology (CeBiTec) & Faculty of Biology, Bielefeld University, Bielefeld, Germany
- Evolution and Diversity, Department of Plant Sciences, University of Cambridge, Cambridge, UK
| | - M Dale
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
| | - M Campbell
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
- Cambridge University Nanjing Centre of Technology and Innovation, Nanjing, P. R. China
| | - S Carobbio
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
- Centro de Investigacion Principe Felipe, Valencia, Spain
| | - Y H Lin
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
- Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - M Vacca
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
- Insterdisciplinary Department of Medicine, Università degli Studi di Bari 'Aldo Moro', Bari, Italy
| | - J Aron-Wisnewsky
- Sorbonne University, INSERM, NutriOmique Research Unit, Paris, France
- Assistance-Publique Hôpitaux de Paris, Nutrition department, Pitié-Salpêtrière hospital, Paris, France
| | - S Mora
- Dept Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Barcelona, Spain
- Institute of Biomedicine, University of Barcelona (IBUB), Barcelona, Spain
| | - M M Masiero
- The Beijer Laboratory and Department of Immunology, Genetics and Pathology, Uppsala University and SciLifeLab, Uppsala, Sweden
| | - A Emmanouilidou
- The Beijer Laboratory and Department of Immunology, Genetics and Pathology, Uppsala University and SciLifeLab, Uppsala, Sweden
| | - S Mukhopadhyay
- MRC Centre for Transplantation Peter Gorer Department of Immunobiology School of Immunology & Microbial Sciences King's College, London, UK
| | - G Dougan
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK
- Division of Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge, UK
| | - M den Hoed
- The Beijer Laboratory and Department of Immunology, Genetics and Pathology, Uppsala University and SciLifeLab, Uppsala, Sweden
| | - R J F Loos
- Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark
| | - J M Fernández-Real
- Department of Diabetes, Endocrinology and Nutrition, Girona Biomedical Research Institute (IDIBGI), University Hospital of Girona Dr Josep Trueta, Girona, Spain
- Department of Medicine, University of Girona, Girona, Spain
- CIBERobn Pathophysiology of Obesity and Nutrition, Institut of Salud Carlos III, Madrid, Spain
| | - D Chiarugi
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK
| | - K Clément
- Sorbonne University, INSERM, NutriOmique Research Unit, Paris, France
- Assistance-Publique Hôpitaux de Paris, Nutrition department, Pitié-Salpêtrière hospital, Paris, France
| | - A Vidal-Puig
- Wellcome-MRC Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK.
- Cambridge University Nanjing Centre of Technology and Innovation, Nanjing, P. R. China.
- Centro de Investigacion Principe Felipe, Valencia, Spain.
| |
Collapse
|
16
|
Li JY, Lin YH, Li N, Wang J, Li YJ. [Laryngo-onycho-cutaneous syndrome caused by variant of LAMA3: a case report]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:207-209. [PMID: 35196767 DOI: 10.3760/cma.j.cn115330-20210316-00131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- J Y Li
- Department of Otorhinolaryngology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
| | - Y H Lin
- Department of Otorhinolaryngology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
| | - N Li
- Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
| | - J Wang
- Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
| | - Y J Li
- Department of Otorhinolaryngology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
| |
Collapse
|
17
|
Jezewski AJ, Lin YH, Reisz JA, Culp-Hill R, Barekatain Y, Yan VC, D'Alessandro A, Muller FL, Odom John AR. Targeting Host Glycolysis as a Strategy for Antimalarial Development. Front Cell Infect Microbiol 2021; 11:730413. [PMID: 34604112 PMCID: PMC8482815 DOI: 10.3389/fcimb.2021.730413] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Accepted: 08/17/2021] [Indexed: 11/13/2022] Open
Abstract
Glycolysis controls cellular energy, redox balance, and biosynthesis. Antiglycolytic therapies are under investigation for treatment of obesity, cancer, aging, autoimmunity, and microbial diseases. Interrupting glycolysis is highly valued as a therapeutic strategy, because glycolytic disruption is generally tolerated in mammals. Unfortunately, anemia is a known dose-limiting side effect of these inhibitors and presents a major caveat to development of antiglycolytic therapies. We developed specific inhibitors of enolase – a critical enzyme in glycolysis – and validated their metabolic and cellular effects on human erythrocytes. Enolase inhibition increases erythrocyte susceptibility to oxidative damage and induces rapid and premature erythrocyte senescence, rather than direct hemolysis. We apply our model of red cell toxicity to address questions regarding erythrocyte glycolytic disruption in the context of Plasmodium falciparum malaria pathogenesis. Our study provides a framework for understanding red blood cell homeostasis under normal and disease states and clarifies the importance of erythrocyte reductive capacity in malaria parasite growth.
Collapse
Affiliation(s)
- Andrew J Jezewski
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.,Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, United States
| | - Yu-Hsi Lin
- Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Julie A Reisz
- Department of Biochemistry and Molecular Genetics, Aurora, CO, United States
| | - Rachel Culp-Hill
- Department of Biochemistry and Molecular Genetics, Aurora, CO, United States
| | - Yasaman Barekatain
- Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Victoria C Yan
- Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Angelo D'Alessandro
- Department of Biochemistry and Molecular Genetics, Aurora, CO, United States
| | - Florian L Muller
- Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.,Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Audrey R Odom John
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.,Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, United States
| |
Collapse
|
18
|
Geng ZY, Xu XD, Wang QH, Jiang Q, Lin YH, Jia CY, Wu TC, He MA. [Association between platelet parameters and risk for stroke in people with different blood pressure levels: Dongfeng-Tongji cohort]. Zhonghua Liu Xing Bing Xue Za Zhi 2021; 42:1580-1585. [PMID: 34814587 DOI: 10.3760/cma.j.cn112338-20210320-00235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Objective: To explore the associations of platelet parameters platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW) and plateletcrit (PCT) with the risk for stroke in people with different blood pressure levels. Methods: All the participants were from Dongfeng-Tongji cohort, including 38 295 retired employees from Dongfeng Motor Corporation at the first follow-up survey. After excluding participants with coronary heart disease, stroke, cancer, history of platelet influential drug use and those with missed data of platelet parameters or blood pressure or lost to follow-up, finally a total of 21 294 participants were included in this study. All the participants completed baseline questionnaires, physical examinations, clinical biochemical tests, and blood sample collection. Cox proportional hazard models were used to estimate the hazard ratios (HRs) and the corresponding 95% confident intervals (CIs) for the associations between platelet parameters and risk for stroke in people with different blood pressure levels. Results: After a mean follow-up of 8.0 years, 1 578 participants developed incident stroke [1 266 ischemic stroke (IS) cases and 312 hemorrhagic stroke (HS) cases]. Compared with the participants with PLT<188×109/L, those with PLT≥188×109/L among hypertension cases were significantly associated with higher risks for stroke and IS (stroke: HR=1.27, 95%CI: 1.12-1.44; IS: HR=1.39, 95%CI: 1.21-1.60). Among hypertension group, compared with participants with PCT<0.165%, PCT≥0.165% were significantly associated with higher risk for stroke (HR=1.15, 95%CI: 1.01-1.30) and lower risk for HS (HR=0.70, 95%CI: 0.53-0.93); Among non-hypertension and hypertension group, PCT ≥0.165% were significantly associated with higher risks of IS (HR=1.27, 95%CI: 1.05-1.54; HR=1.31, 95%CI: 1.14-1.50). MPV and PDW were not significantly associated with risk for stroke. Risk for stroke increased significantly in hypertension cases with different platelet parameters levels compared with non-hypertension cases with lower levels of each platelet parameters. Conclusion: Higher levels of PLT and PCT could increase the risks for stroke and IS in middle-aged and elderly hypertension patients, and lower levels of PCT could decrease the risk for HS in hypertension patients.
Collapse
Affiliation(s)
- Z Y Geng
- Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - X D Xu
- Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Q H Wang
- Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Q Jiang
- Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Y H Lin
- Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - C Y Jia
- Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - T C Wu
- Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - M A He
- Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| |
Collapse
|
19
|
Amenomori M, Bao YW, Bi XJ, Chen D, Chen TL, Chen WY, Chen X, Chen Y, Cui SW, Ding LK, Fang JH, Fang K, Feng CF, Feng Z, Feng ZY, Gao Q, Gomi A, Gou QB, Guo YQ, Guo YY, He HH, He ZT, Hibino K, Hotta N, Hu H, Hu HB, Huang J, Jia HY, Jiang L, Jiang P, Jin HB, Kasahara K, Katayose Y, Kato C, Kato S, Kawata K, Kozai M, Kurashige D, Le GM, Li AF, Li HJ, Li WJ, Li Y, Lin YH, Liu B, Liu C, Liu JS, Liu LY, Liu MY, Liu W, Liu XL, Lou YQ, Lu H, Meng XR, Munakata K, Nakada H, Nakamura Y, Nakazawa Y, Nanjo H, Ning CC, Nishizawa M, Ohnishi M, Ohura T, Okukawa S, Ozawa S, Qian L, Qian X, Qian XL, Qu XB, Saito T, Sakata M, Sako T, Sako TK, Shao J, Shibata M, Shiomi A, Sugimoto H, Takano W, Takita M, Tan YH, Tateyama N, Torii S, Tsuchiya H, Udo S, Wang H, Wang YP, Wu HR, Wu Q, Xu JL, Xue L, Yamamoto Y, Yang Z, Yao YQ, Yin J, Yokoe Y, Yu NP, Yuan AF, Zhai LM, Zhang CP, Zhang HM, Zhang JL, Zhang X, Zhang XY, Zhang Y, Zhang Y, Zhang Y, Zhao SP, Zhou XX. Gamma-Ray Observation of the Cygnus Region in the 100-TeV Energy Region. Phys Rev Lett 2021; 127:031102. [PMID: 34328784 DOI: 10.1103/physrevlett.127.031102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 04/30/2021] [Accepted: 06/15/2021] [Indexed: 06/13/2023]
Abstract
We report observations of gamma-ray emissions with energies in the 100-TeV energy region from the Cygnus region in our Galaxy. Two sources are significantly detected in the directions of the Cygnus OB1 and OB2 associations. Based on their positional coincidences, we associate one with a pulsar PSR J2032+4127 and the other mainly with a pulsar wind nebula PWN G75.2+0.1, with the pulsar moving away from its original birthplace situated around the centroid of the observed gamma-ray emission. This work would stimulate further studies of particle acceleration mechanisms at these gamma-ray sources.
Collapse
Affiliation(s)
- M Amenomori
- Department of Physics, Hirosaki University, Hirosaki 036-8561, Japan
| | - Y W Bao
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - X J Bi
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - D Chen
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - T L Chen
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - W Y Chen
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Xu Chen
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Chen
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - S W Cui
- Department of Physics, Hebei Normal University, Shijiazhuang 050016, China
| | - L K Ding
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J H Fang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - K Fang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - C F Feng
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
| | - Zhaoyang Feng
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Z Y Feng
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - Qi Gao
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - A Gomi
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - Q B Gou
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Q Guo
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Y Guo
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H H He
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Z T He
- Department of Physics, Hebei Normal University, Shijiazhuang 050016, China
| | - K Hibino
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - N Hotta
- Faculty of Education, Utsunomiya University, Utsunomiya 321-8505, Japan
| | - Haibing Hu
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - H B Hu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J Huang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H Y Jia
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - L Jiang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - P Jiang
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - H B Jin
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - K Kasahara
- Faculty of Systems Engineering, Shibaura Institute of Technology, Omiya 330-8570, Japan
| | - Y Katayose
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - C Kato
- Department of Physics, Shinshu University, Matsumoto 390-8621, Japan
| | - S Kato
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - K Kawata
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - M Kozai
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara 252-5210, Japan
| | - D Kurashige
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - G M Le
- National Center for Space Weather, China Meteorological Administration, Beijing 100081, China
| | - A F Li
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
- School of Information Science and Engineering, Shandong Agriculture University, Taian 271018, China
| | - H J Li
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - W J Li
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - Y Li
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - Y H Lin
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - B Liu
- Department of Astronomy, School of Physical Sciences, University of Science and Technology of China, Hefei, Anhui 230026, China
| | - C Liu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J S Liu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - L Y Liu
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - M Y Liu
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - W Liu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X L Liu
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - Y-Q Lou
- Department of Physics and Tsinghua Centre for Astrophysics (THCA), Tsinghua University, Beijing 100084, China
- Tsinghua University-National Astronomical Observatories of China (NAOC) Joint Research Center for Astrophysics, Tsinghua University, Beijing 100084, China
- Department of Astronomy, Tsinghua University, Beijing 100084, China
| | - H Lu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X R Meng
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - K Munakata
- Department of Physics, Shinshu University, Matsumoto 390-8621, Japan
| | - H Nakada
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - Y Nakamura
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - Y Nakazawa
- College of Industrial Technology, Nihon University, Narashino 275-8575, Japan
| | - H Nanjo
- Department of Physics, Hirosaki University, Hirosaki 036-8561, Japan
| | - C C Ning
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - M Nishizawa
- National Institute of Informatics, Tokyo 101-8430, Japan
| | - M Ohnishi
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - T Ohura
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - S Okukawa
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - S Ozawa
- National Institute of Information and Communications Technology, Tokyo 184-8795, Japan
| | - L Qian
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - X Qian
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - X L Qian
- Department of Mechanical and Electrical Engineering, Shangdong Management University, Jinan 250357, China
| | - X B Qu
- College of Science, China University of Petroleum, Qingdao 266555, China
| | - T Saito
- Tokyo Metropolitan College of Industrial Technology, Tokyo 116-8523, Japan
| | - M Sakata
- Department of Physics, Konan University, Kobe 658-8501, Japan
| | - T Sako
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - T K Sako
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - J Shao
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
| | - M Shibata
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - A Shiomi
- College of Industrial Technology, Nihon University, Narashino 275-8575, Japan
| | - H Sugimoto
- Shonan Institute of Technology, Fujisawa 251-8511, Japan
| | - W Takano
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - M Takita
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - Y H Tan
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - N Tateyama
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - S Torii
- Research Institute for Science and Engineering, Waseda University, Tokyo 162-0044, Japan
| | - H Tsuchiya
- Japan Atomic Energy Agency, Tokai-mura 319-1195, Japan
| | - S Udo
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - H Wang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y P Wang
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - H R Wu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Q Wu
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - J L Xu
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - L Xue
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
| | - Y Yamamoto
- Department of Physics, Konan University, Kobe 658-8501, Japan
| | - Z Yang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Q Yao
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - J Yin
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - Y Yokoe
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - N P Yu
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - A F Yuan
- Department of Mathematics and Physics, Tibet University, Lhasa 850000, China
| | - L M Zhai
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - C P Zhang
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - H M Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J L Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X Zhang
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - X Y Zhang
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
| | - Y Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Yi Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210034, China
| | - Ying Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - S P Zhao
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X X Zhou
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| |
Collapse
|
20
|
Barekatain Y, Ackroyd JJ, Yan VC, Khadka S, Wang L, Chen KC, Poral AH, Tran T, Georgiou DK, Arthur K, Lin YH, Satani N, Ballato ES, Behr EI, deCarvalho AC, Verhaak RGW, de Groot J, Huse JT, Asara JM, Kalluri R, Muller FL. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nat Commun 2021; 12:4228. [PMID: 34244484 PMCID: PMC8270912 DOI: 10.1038/s41467-021-24240-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Accepted: 06/04/2021] [Indexed: 02/07/2023] Open
Abstract
Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. Homozygous MTAP-deleted cell lines in culture show elevation of MTAP’s substrate metabolite, methylthioadenosine (MTA). High levels of MTA inhibit protein arginine methyltransferase 5 (PRMT5), which sensitizes MTAP-deleted cells to PRMT5 and methionine adenosyltransferase 2A (MAT2A) inhibition. While this concept has been extensively corroborated in vitro, the clinical relevance relies on exhibiting significant MTA accumulation in human glioblastoma. In this work, using comprehensive metabolomic profiling, we show that MTA secreted by MTAP-deleted cells in vitro results in high levels of extracellular MTA. We further demonstrate that homozygous MTAP-deleted primary glioblastoma tumors do not significantly accumulate MTA in vivo due to metabolism of MTA by MTAP-expressing stroma. These findings highlight metabolic discrepancies between in vitro models and primary human tumors that must be considered when developing strategies for precision therapies targeting glioblastoma with homozygous MTAP deletion. The metabolite methylthioadenosine (MTA) inhibits PRMT5. Therefore, MTA accumulation due to MTA phosphorylase (MTAP) deletion has been proposed as a vulnerability for PRMT5-targeted therapy in cancer. Here, the authors show that MTA does not accumulate in MTAP-deficient cancer cells but is secreted and metabolized by MTAP-intact cells in the tumour microenvironment.
Collapse
Affiliation(s)
- Yasaman Barekatain
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .,Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .,MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA.
| | - Jeffrey J Ackroyd
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Victoria C Yan
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Sunada Khadka
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Lin Wang
- Department of Chemistry and Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA
| | - Ko-Chien Chen
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX, USA
| | - Anton H Poral
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Theresa Tran
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Dimitra K Georgiou
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kenisha Arthur
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yu-Hsi Lin
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nikunj Satani
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Elliot S Ballato
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Eliot I Behr
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ana C deCarvalho
- Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
| | - Roel G W Verhaak
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - John de Groot
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason T Huse
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John M Asara
- Department of Medicine, Harvard Medical School, and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Raghu Kalluri
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Florian L Muller
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .,SPOROS Bioventures, Houston, TX, USA.
| |
Collapse
|
21
|
Lin HK, Huang CW, Lin YH, Chuang WS, Huang JC. Effects of Accumulated Energy on Nanoparticle Formation in Pulsed-Laser Dewetting of AgCu Thin Films. Nanoscale Res Lett 2021; 16:110. [PMID: 34191148 PMCID: PMC8245639 DOI: 10.1186/s11671-021-03564-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/06/2021] [Accepted: 06/14/2021] [Indexed: 06/13/2023]
Abstract
Ag50Cu50 films were deposited on glass substrates by a sputtering system. Effects of accumulated energy on nanoparticle formation in pulse-laser dewetting of AgCu films were investigated. The results showed that the properties of the dewetted films were found to be dependent on the magnitude of the energy accumulated in the film. For a low energy accumulation, the two distinct nanoparticles had rice-shaped/Ag60Cu40 and hemispherical/Ag80Cu20. Moreover, the absorption spectra contained two peaks at 700 nm and 500 nm, respectively. By contrast, for a high energy accumulation, the nanoparticles had a consistent composition of Ag60Cu40, a mean diameter of 100 nm and a peak absorption wavelength of 550 nm. Overall, the results suggest that a higher Ag content of the induced nanoparticles causes a blue shift of the absorption spectrum, while a smaller particle size induces a red shift.
Collapse
Affiliation(s)
- H K Lin
- Graduate Institute of Materials Engineering, National Pingtung University of Science and Technology, 1, Hseuhfu Road, Pingtung 912, Taiwan, ROC.
| | - C W Huang
- Graduate Institute of Materials Engineering, National Pingtung University of Science and Technology, 1, Hseuhfu Road, Pingtung 912, Taiwan, ROC
- Department of Plant Medicine, National Pingtung University of Science and Technology, 1, Hseuhfu Road, Pingtung 912, Taiwan, ROC
| | - Y H Lin
- Department of Plant Medicine, National Pingtung University of Science and Technology, 1, Hseuhfu Road, Pingtung 912, Taiwan, ROC
| | - W S Chuang
- Department of Materials Science and Engineering, Hong Kong Institute for Advanced Study, City University of Hong Kong, Kowloon, Hong Kong.
| | - J C Huang
- Department of Materials Science and Engineering, Hong Kong Institute for Advanced Study, City University of Hong Kong, Kowloon, Hong Kong
| |
Collapse
|
22
|
Khadka S, Arthur K, Barekatain Y, Behr E, Washington M, Ackroyd J, Crowley K, Suriyamongkol P, Lin YH, Pham CD, Zielinski R, Trujillo M, Galligan J, Georgiou DK, Asara J, Muller F. Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma. Cancer Metab 2021; 9:27. [PMID: 34172075 PMCID: PMC8228515 DOI: 10.1186/s40170-021-00259-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Accepted: 04/18/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Reprogramming of metabolic pathways is crucial to satisfy the bioenergetic and biosynthetic demands and maintain the redox status of rapidly proliferating cancer cells. In tumors, the tricarboxylic acid (TCA) cycle generates biosynthetic intermediates and must be replenished (anaplerosis), mainly from pyruvate and glutamine. We recently described a novel enolase inhibitor, HEX, and its pro-drug POMHEX. Since glycolysis inhibition would deprive the cell of a key source of pyruvate, we hypothesized that enolase inhibitors might inhibit anaplerosis and synergize with other inhibitors of anaplerosis, such as the glutaminase inhibitor, CB-839. METHODS We analyzed polar metabolites in sensitive (ENO1-deleted) and resistant (ENO1-WT) glioma cells treated with enolase and glutaminase inhibitors. We investigated whether sensitivity to enolase inhibitors could be attenuated by exogenous anaplerotic metabolites. We also determined the synergy between enolase inhibitors and the glutaminase inhibitor CB-839 in glioma cells in vitro and in vivo in both intracranial and subcutaneous tumor models. RESULTS Metabolomic profiling of ENO1-deleted glioma cells treated with the enolase inhibitor revealed a profound decrease in the TCA cycle metabolites with the toxicity reversible upon exogenous supplementation of supraphysiological levels of anaplerotic substrates, including pyruvate. ENO1-deleted cells also exhibited selective sensitivity to the glutaminase inhibitor CB-839, in a manner rescuable by supplementation of anaplerotic substrates or plasma-like media PlasmaxTM. In vitro, the interaction of these two drugs yielded a strong synergistic interaction but the antineoplastic effects of CB-839 as a single agent in ENO1-deleted xenograft tumors in vivo were modest in both intracranial orthotopic tumors, where the limited efficacy could be attributed to the blood-brain barrier (BBB), and subcutaneous xenografts, where BBB penetration is not an issue. This contrasts with the enolase inhibitor HEX, which, despite its negative charge, achieved antineoplastic effects in both intracranial and subcutaneous tumors. CONCLUSION Together, these data suggest that at least for ENO1-deleted gliomas, tumors in vivo-unlike cells in culture-show limited dependence on glutaminolysis and instead primarily depend on glycolysis for anaplerosis. Our findings reinforce the previously reported metabolic idiosyncrasies of in vitro culture and suggest that cell culture media nutrient composition more faithful to the in vivo environment will more accurately predict in vivo efficacy of metabolism targeting drugs.
Collapse
Affiliation(s)
- Sunada Khadka
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA ,grid.240145.60000 0001 2291 4776Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX USA ,grid.240145.60000 0001 2291 4776MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX USA
| | - Kenisha Arthur
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - Yasaman Barekatain
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA ,grid.240145.60000 0001 2291 4776Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX USA ,grid.240145.60000 0001 2291 4776MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX USA
| | - Eliot Behr
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - Mykia Washington
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - Jeffrey Ackroyd
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA ,grid.240145.60000 0001 2291 4776MD Anderson UT Health Graduate School of Biomedical Sciences, Houston, TX USA
| | - Kaitlyn Crowley
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - Pornpa Suriyamongkol
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - Yu-Hsi Lin
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - Cong-Dat Pham
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - Rafal Zielinski
- grid.240145.60000 0001 2291 4776Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - Marissa Trujillo
- grid.134563.60000 0001 2168 186XDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ USA
| | - James Galligan
- grid.134563.60000 0001 2168 186XDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ USA
| | - Dimitra K. Georgiou
- grid.240145.60000 0001 2291 4776Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX USA
| | - John Asara
- grid.239395.70000 0000 9011 8547Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA USA
| | | |
Collapse
|
23
|
Amenomori M, Bao YW, Bi XJ, Chen D, Chen TL, Chen WY, Chen X, Chen Y, Cui SW, Ding LK, Fang JH, Fang K, Feng CF, Feng Z, Feng ZY, Gao Q, Gou QB, Guo YQ, Guo YY, He HH, He ZT, Hibino K, Hotta N, Hu H, Hu HB, Huang J, Jia HY, Jiang L, Jin HB, Kasahara K, Katayose Y, Kato C, Kato S, Kawata K, Kihara W, Ko Y, Kozai M, Le GM, Li AF, Li HJ, Li WJ, Lin YH, Liu B, Liu C, Liu JS, Liu MY, Liu W, Lou YQ, Lu H, Meng XR, Munakata K, Nakada H, Nakamura Y, Nanjo H, Nishizawa M, Ohnishi M, Ohura T, Ozawa S, Qian XL, Qu XB, Saito T, Sakata M, Sako TK, Shao J, Shibata M, Shiomi A, Sugimoto H, Takano W, Takita M, Tan YH, Tateyama N, Torii S, Tsuchiya H, Udo S, Wang H, Wu HR, Xue L, Yamamoto Y, Yang Z, Yokoe Y, Yuan AF, Zhai LM, Zhang HM, Zhang JL, Zhang X, Zhang XY, Zhang Y, Zhang Y, Zhang Y, Zhao SP, Zhou XX. First Detection of sub-PeV Diffuse Gamma Rays from the Galactic Disk: Evidence for Ubiquitous Galactic Cosmic Rays beyond PeV Energies. Phys Rev Lett 2021; 126:141101. [PMID: 33891464 DOI: 10.1103/physrevlett.126.141101] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Revised: 01/05/2021] [Accepted: 01/21/2021] [Indexed: 06/12/2023]
Abstract
We report, for the first time, the long-awaited detection of diffuse gamma rays with energies between 100 TeV and 1 PeV in the Galactic disk. Particularly, all gamma rays above 398 TeV are observed apart from known TeV gamma-ray sources and compatible with expectations from the hadronic emission scenario in which gamma rays originate from the decay of π^{0}'s produced through the interaction of protons with the interstellar medium in the Galaxy. This is strong evidence that cosmic rays are accelerated beyond PeV energies in our Galaxy and spread over the Galactic disk.
Collapse
Affiliation(s)
- M Amenomori
- Department of Physics, Hirosaki University, Hirosaki 036-8561, Japan
| | - Y W Bao
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - X J Bi
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - D Chen
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - T L Chen
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - W Y Chen
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Xu Chen
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Chen
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - S W Cui
- Department of Physics, Hebei Normal University, Shijiazhuang 050016, China
| | - L K Ding
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J H Fang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - K Fang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - C F Feng
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
| | - Zhaoyang Feng
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Z Y Feng
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - Qi Gao
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - Q B Gou
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Q Guo
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Y Guo
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H H He
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Z T He
- Department of Physics, Hebei Normal University, Shijiazhuang 050016, China
| | - K Hibino
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - N Hotta
- Faculty of Education, Utsunomiya University, Utsunomiya 321-8505, Japan
| | - Haibing Hu
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - H B Hu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J Huang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H Y Jia
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - L Jiang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H B Jin
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - K Kasahara
- Faculty of Systems Engineering, Shibaura Institute of Technology, Omiya 330-8570, Japan
| | - Y Katayose
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - C Kato
- Department of Physics, Shinshu University, Matsumoto 390-8621, Japan
| | - S Kato
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - K Kawata
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - W Kihara
- Department of Physics, Shinshu University, Matsumoto 390-8621, Japan
| | - Y Ko
- Department of Physics, Shinshu University, Matsumoto 390-8621, Japan
| | - M Kozai
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara 252-5210, Japan
| | - G M Le
- National Center for Space Weather, China Meteorological Administration, Beijing 100081, China
| | - A F Li
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
- School of Information Science and Engineering, Shandong Agriculture University, Taian 271018, China
| | - H J Li
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - W J Li
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - Y H Lin
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - B Liu
- Department of Astronomy, School of Physical Sciences, University of Science and Technology of China, Hefei, Anhui 230026, China
| | - C Liu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J S Liu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - M Y Liu
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - W Liu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y-Q Lou
- Department of Physics and Tsinghua Centre for Astrophysics (THCA), Tsinghua University, Beijing 100084, China
- Tsinghua University-National Astronomical Observatories of China (NAOC) Joint Research Center for Astrophysics, Tsinghua University, Beijing 100084, China
- Department of Astronomy, Tsinghua University, Beijing 100084, China
| | - H Lu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X R Meng
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - K Munakata
- Department of Physics, Shinshu University, Matsumoto 390-8621, Japan
| | - H Nakada
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - Y Nakamura
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H Nanjo
- Department of Physics, Hirosaki University, Hirosaki 036-8561, Japan
| | - M Nishizawa
- National Institute of Informatics, Tokyo 101-8430, Japan
| | - M Ohnishi
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - T Ohura
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - S Ozawa
- National Institute of Information and Communications Technology, Tokyo 184-8795, Japan
| | - X L Qian
- Department of Mechanical and Electrical Engineering, Shandong Management University, Jinan 250357, China
| | - X B Qu
- College of Science, China University of Petroleum, Qingdao, 266555, China
| | - T Saito
- Tokyo Metropolitan College of Industrial Technology, Tokyo 116-8523, Japan
| | - M Sakata
- Department of Physics, Konan University, Kobe 658-8501, Japan
| | - T K Sako
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - J Shao
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
| | - M Shibata
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - A Shiomi
- College of Industrial Technology, Nihon University, Narashino 275-8575, Japan
| | - H Sugimoto
- Shonan Institute of Technology, Fujisawa 251-8511, Japan
| | - W Takano
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - M Takita
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - Y H Tan
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - N Tateyama
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - S Torii
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan
| | - H Tsuchiya
- Japan Atomic Energy Agency, Tokai-mura 319-1195, Japan
| | - S Udo
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - H Wang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H R Wu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - L Xue
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
| | - Y Yamamoto
- Department of Physics, Konan University, Kobe 658-8501, Japan
| | - Z Yang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Yokoe
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - A F Yuan
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - L M Zhai
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - H M Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J L Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X Zhang
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - X Y Zhang
- Institute of Frontier and Interdisciplinary Science and Key Laboratory of Particle Physics and Particle Irradiation (MOE), Shandong University, Qingdao 266237, China
| | - Y Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Yi Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210034, China
| | - Ying Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - S P Zhao
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X X Zhou
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| |
Collapse
|
24
|
Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab 2021; 3:122. [PMID: 33340032 DOI: 10.1038/s42255-020-00335-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Yu-Hsi Lin
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nikunj Satani
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Institute of Stroke and Cerebrovascular Disease, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Naima Hammoudi
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Victoria C Yan
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yasaman Barekatain
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sunada Khadka
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jeffrey J Ackroyd
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Dimitra K Georgiou
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Cong-Dat Pham
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kenisha Arthur
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - David Maxwell
- Institutional Analytics & Informatics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Paul G Leonard
- Core for Biomolecular Structure and Function, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Barbara Czako
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Federica Pisaneschi
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Pijus Mandal
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yuting Sun
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Rafal Zielinski
- Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Susana Castro Pando
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Xiaobo Wang
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Theresa Tran
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Quanyu Xu
- Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Qi Wu
- Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yongying Jiang
- Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Zhijun Kang
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John M Asara
- Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Waldemar Priebe
- Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - William Bornmann
- Director of Drug Discovery and Development, Advanced Organic Synthesis LLC, Houston, Texas, USA
| | - Joseph R Marszalek
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ronald A DePinho
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Florian L Muller
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
25
|
Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab 2020; 2:1413-1426. [PMID: 33230295 PMCID: PMC7744354 DOI: 10.1038/s42255-020-00313-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 10/15/2020] [Indexed: 12/15/2022]
Abstract
Inhibiting glycolysis remains an aspirational approach for the treatment of cancer. We have previously identified a subset of cancers harbouring homozygous deletion of the glycolytic enzyme enolase (ENO1) that have exceptional sensitivity to inhibition of its redundant paralogue, ENO2, through a therapeutic strategy known as collateral lethality. Here, we show that a small-molecule enolase inhibitor, POMHEX, can selectively kill ENO1-deleted glioma cells at low-nanomolar concentrations and eradicate intracranial orthotopic ENO1-deleted tumours in mice at doses well-tolerated in non-human primates. Our data provide an in vivo proof of principle of the power of collateral lethality in precision oncology and demonstrate the utility of POMHEX for glycolysis inhibition with potential use across a range of therapeutic settings.
Collapse
Affiliation(s)
- Yu-Hsi Lin
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nikunj Satani
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Institute of Stroke and Cerebrovascular Disease, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Naima Hammoudi
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Victoria C Yan
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yasaman Barekatain
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sunada Khadka
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jeffrey J Ackroyd
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Dimitra K Georgiou
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Cong-Dat Pham
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kenisha Arthur
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - David Maxwell
- Institutional Analytics & Informatics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Paul G Leonard
- Core for Biomolecular Structure and Function, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Barbara Czako
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Federica Pisaneschi
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Pijus Mandal
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yuting Sun
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Rafal Zielinski
- Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Susana Castro Pando
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Xiaobo Wang
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Theresa Tran
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Quanyu Xu
- Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Qi Wu
- Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yongying Jiang
- Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Zhijun Kang
- Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John M Asara
- Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Waldemar Priebe
- Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - William Bornmann
- Director of Drug Discovery and Development, Advanced Organic Synthesis LLC, Houston, Texas, USA
| | - Joseph R Marszalek
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ronald A DePinho
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Florian L Muller
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
26
|
Khadka S, Lin YH, Ackroyd J, Arthur K, Barekatain Y, Poral A, Tran T, Georgiou D, de Groot J, Huse J, Asara J, Muller F. TAMI-62. ANGIOGENESIS INHIBITORS STRONGLY SYNERGIZE WITH THERAPEUTICS TARGETING TUMOR METABOLISM. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Angiogenesis inhibition has become a mainstay of oncology despite having fallen short of its early promise. As originally envisioned, angiogenesis inhibition would cut off the blood supply, deprive tumor cells of key nutrients, leading to their demise. In practice, while there is evidence that tumors under angiogenesis treatment do in fact exhibit some degree of metabolic stress, this is stress is not sufficient to induce significant cancer cell death. We posit that the full potential of angiogenesis inhibition can be realized by the combination of angiogenesis inhibition with emerging tumor metabolism targeting therapies. Because tumors under angiogenesis inhibition are already in a state of nutrient stress, the effects of metabolically targeted therapies such as amino acid depletion (e.g. asparginase, methionine restriction), inhibitors of stress adaption (AMPK and GCN2 inhibitors) or energy metabolism (e.g. IACS-010759, Metformin, POMHEX) stand to dramatically increase in potency whilst remaining selective for (angiogenic) tumor versus (non-angiogenic) normal tissue. Here, we provide proof-of-principal for this thesis. First, we performed metabolomic profiling of angiogenesis-inhibited tumors, which corroborates as state of nutrient stress in angiogenesis-inhibited tumors. Second, we demonstrate dramatic anti-neoplastic synergy (effectively curing of xenografted tumor-bearing mice, irrespective of initial tumor size), without enhanced adverse toxicities, between the OxPhos inhibitor IACS-010759 and the angiogenesis tyrosine kinase inhibitor, Tivozanib. The same results were recapitulated with the anti-VEGFA antibody, Avastin, and the OxPhos inhibitor could be substituted with the Enolase inhibitor HEX, with similar effects. The synergy was observed in a broad range of tumor types, even those without clear genetic susceptibilities. Together, these results suggest that Angiogenesis inhibitors synergize broadly with cancer therapies targeting metabolism, allowing the realization of the full potential of these previously disappointing drugs. Our results warrant systematic combination clinical trials between angiogenesis inhibitors and established, as well as emerging anti-metabolic cancer therapies.
Collapse
Affiliation(s)
- Sunada Khadka
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yu-Hsi Lin
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jeffrey Ackroyd
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kenisha Arthur
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Anton Poral
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Theresa Tran
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - John de Groot
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason Huse
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John Asara
- Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Florian Muller
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
27
|
Maitituoheti M, Keung EZ, Tang M, Yan L, Alam H, Han G, Singh AK, Raman AT, Terranova C, Sarkar S, Orouji E, Amin SB, Sharma S, Williams M, Samant NS, Dhamdhere M, Zheng N, Shah T, Shah A, Axelrad JB, Anvar NE, Lin YH, Jiang S, Chang EQ, Ingram DR, Wang WL, Lazar A, Lee MG, Muller F, Wang L, Ying H, Rai K. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Rep 2020; 33:108293. [PMID: 33086062 PMCID: PMC7649750 DOI: 10.1016/j.celrep.2020.108293] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 08/11/2020] [Accepted: 09/29/2020] [Indexed: 12/16/2022] Open
Abstract
Histone methyltransferase KMT2D harbors frequent loss-of-function somatic point mutations in several tumor types, including melanoma. Here, we identify KMT2D as a potent tumor suppressor in melanoma through an in vivo epigenome-focused pooled RNAi screen and confirm the finding by using a genetically engineered mouse model (GEMM) based on conditional and melanocyte-specific deletion of KMT2D. KMT2D-deficient tumors show substantial reprogramming of key metabolic pathways, including glycolysis. KMT2D deficiency aberrantly upregulates glycolysis enzymes, intermediate metabolites, and glucose consumption rates. Mechanistically, KMT2D loss causes genome-wide reduction of H3K4me1-marked active enhancer chromatin states. Enhancer loss and subsequent repression of IGFBP5 activates IGF1R-AKT to increase glycolysis in KMT2D-deficient cells. Pharmacological inhibition of glycolysis and insulin growth factor (IGF) signaling reduce proliferation and tumorigenesis preferentially in KMT2D-deficient cells. We conclude that KMT2D loss promotes tumorigenesis by facilitating an increased use of the glycolysis pathway for enhanced biomass needs via enhancer reprogramming, thus presenting an opportunity for therapeutic intervention through glycolysis or IGF pathway inhibitors.
Collapse
Affiliation(s)
- Mayinuer Maitituoheti
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Emily Z Keung
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ming Tang
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Liang Yan
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Hunain Alam
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Guangchun Han
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Anand K Singh
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ayush T Raman
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate Program in Quantitative Sciences, Baylor College of Medicine, Houston, TX, USA
| | - Christopher Terranova
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sharmistha Sarkar
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Elias Orouji
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Samir B Amin
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Sneha Sharma
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Maura Williams
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Neha S Samant
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Mayura Dhamdhere
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Norman Zheng
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tara Shah
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Amiksha Shah
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jacob B Axelrad
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nazanin E Anvar
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yu-Hsi Lin
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Shan Jiang
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Edward Q Chang
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Davis R Ingram
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Wei-Lien Wang
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Alexander Lazar
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Min Gyu Lee
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Florian Muller
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Linghua Wang
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Haoqiang Ying
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kunal Rai
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate Program in Quantitative Sciences, Baylor College of Medicine, Houston, TX, USA; Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
28
|
Santos JC, Goulart LF, Giansante L, Lin YH, Sirico ACA, Ng AH, Tsapaki V, Bezak E, Ng KH. Leadership and mentoring in medical physics: The experience of a medical physics international mentoring program. Phys Med 2020; 76:337-344. [PMID: 32759035 DOI: 10.1016/j.ejmp.2020.07.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 07/09/2020] [Accepted: 07/16/2020] [Indexed: 10/23/2022] Open
Abstract
Mentoring aims to improve careers and create benefits for the participants' personal and professional lives. Mentoring can be an individual or a shared experience for a group, while the mentor's role remains the same in both models. Mentors should increase confidence, teach, inspire, and set examples, helping the mentees to mould their path, contributing to the pursuit of their personal and professional goals. This study aims to report on the experience of early-career medical physics professionals and postgraduate students participating in a global mentoring program and to assess the impact of this activity on their professional development. The objectives of this mentoring program are to develop leadership roles among young medical physicists and to provide guidance and support. An online questionnaire was administered to the mentee participants. The analysis of their responses is reported in this work and the current status of the programme was examined using a SWOT analysis. In general, the mentoring experience had a positive impact on the mentees. The mentors were found especially helpful in the decision-making situations and in other conflicts that may arise with career development. Additionally, the mentees felt that mentoring contributed to the development of leadership skills required for the job market and assist in personal development. This paper concludes that participation of young medical physicists in a mentoring group program is beneficial to their career and therefore should be encouraged.
Collapse
Affiliation(s)
- J C Santos
- Institute of Physics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
| | - L F Goulart
- Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil
| | - L Giansante
- Department of Physics, The Royal Marsden NHS Foundation Trust, London, UK
| | - Y H Lin
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
| | - A C A Sirico
- Department of Nuclear Physics, Institute of Physics, University of São Paulo, São Paulo, SP, Brazil
| | - A H Ng
- Department of Radiotherapy and Oncology, National Cancer Institute, Putrajaya, Malaysia
| | - V Tsapaki
- Konstantopoulio - Agia Olga General Hospital, Medical Physics Department, Athens, Greece
| | - E Bezak
- Cancer Research Institute, University of South Australia, Adelaide, SA, Australia; Department of Physics, University of Adelaide, Adelaide, SA, Australia
| | - K H Ng
- Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| |
Collapse
|
29
|
Lin YH, Rui XQ, Li YJ. [Post-transplantation lymphoproliferative disorder of the larynx after pediatric transplantation: report of three cases]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2020; 55:698-701. [PMID: 32668882 DOI: 10.3760/cma.j.cn115330-20190930-00608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Y H Lin
- Department of Otolaryngology, Shanghai Children's Medical Center of Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
| | - X Q Rui
- Department of Otolaryngology, Shanghai Children's Medical Center of Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
| | - Y J Li
- Department of Otolaryngology, Shanghai Children's Medical Center of Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
| |
Collapse
|
30
|
Al Kharusi S, Anton G, Badhrees I, Barbeau PS, Beck D, Belov V, Bhatta T, Breidenbach M, Brunner T, Cao GF, Cen WR, Chambers C, Cleveland B, Coon M, Craycraft A, Daniels T, Darroch L, Daugherty SJ, Davis J, Delaquis S, Der Mesrobian-Kabakian A, DeVoe R, Dilling J, Dolgolenko A, Dolinski MJ, Echevers J, Fairbank W, Fairbank D, Farine J, Feyzbakhsh S, Fierlinger P, Fudenberg D, Gautam P, Gornea R, Gratta G, Hall C, Hansen EV, Hoessl J, Hufschmidt P, Hughes M, Iverson A, Jamil A, Jessiman C, Jewell MJ, Johnson A, Karelin A, Kaufman LJ, Koffas T, Kostensalo J, Krücken R, Kuchenkov A, Kumar KS, Lan Y, Larson A, Lenardo BG, Leonard DS, Li GS, Li S, Li Z, Licciardi C, Lin YH, MacLellan R, McElroy T, Michel T, Mong B, Moore DC, Murray K, Nakarmi P, Njoya O, Nusair O, Odian A, Ostrovskiy I, Piepke A, Pocar A, Retière F, Robinson AL, Rowson PC, Ruddell D, Runge J, Schmidt S, Sinclair D, Skarpaas K, Soma AK, Stekhanov V, Suhonen J, Tarka M, Thibado S, Todd J, Tolba T, Totev TI, Tsang R, Veenstra B, Veeraraghavan V, Vogel P, Vuilleumier JL, Wagenpfeil M, Watkins J, Weber M, Wen LJ, Wichoski U, Wrede G, Wu SX, Xia Q, Yahne DR, Yang L, Yen YR, Zeldovich OY, Ziegler T. Measurement of the Spectral Shape of the β-Decay of ^{137}Xe to the Ground State of ^{137}Cs in EXO-200 and Comparison with Theory. Phys Rev Lett 2020; 124:232502. [PMID: 32603173 DOI: 10.1103/physrevlett.124.232502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 04/17/2020] [Accepted: 05/07/2020] [Indexed: 06/11/2023]
Abstract
We report on a comparison between the theoretically predicted and experimentally measured spectra of the first-forbidden nonunique β-decay transition ^{137}Xe(7/2^{-})→^{137}Cs(7/2^{+}). The experimental data were acquired by the EXO-200 experiment during a deployment of an AmBe neutron source. The ultralow background environment of EXO-200, together with dedicated source deployment and analysis procedures, allowed for collection of a pure sample of the decays, with an estimated signal to background ratio of more than 99 to 1 in the energy range from 1075 to 4175 keV. In addition to providing a rare and accurate measurement of the first-forbidden nonunique β-decay shape, this work constitutes a novel test of the calculated electron spectral shapes in the context of the reactor antineutrino anomaly and spectral bump.
Collapse
Affiliation(s)
- S Al Kharusi
- Physics Department, McGill University, Montreal, Quebec H3A 2T8, Canada
| | - G Anton
- Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - I Badhrees
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - P S Barbeau
- Department of Physics, Duke University, and Triangle Universities Nuclear Laboratory (TUNL), Durham, North Carolina 27708, USA
| | - D Beck
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - V Belov
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute", Moscow 117218, Russia
| | - T Bhatta
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - M Breidenbach
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - T Brunner
- Physics Department, McGill University, Montreal, Quebec H3A 2T8, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - G F Cao
- Institute of High Energy Physics, Beijing 100049, China
| | - W R Cen
- Institute of High Energy Physics, Beijing 100049, China
| | - C Chambers
- Physics Department, McGill University, Montreal, Quebec H3A 2T8, Canada
| | - B Cleveland
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - M Coon
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - A Craycraft
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - T Daniels
- Department of Physics and Physical Oceanography, University of North Carolina at Wilmington, Wilmington, North Carolina 28403, USA
| | - L Darroch
- Physics Department, McGill University, Montreal, Quebec H3A 2T8, Canada
| | - S J Daugherty
- Physics Department and CEEM, Indiana University, Bloomington, Indiana 47405, USA
| | - J Davis
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - S Delaquis
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | | | - R DeVoe
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - J Dilling
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A Dolgolenko
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute", Moscow 117218, Russia
| | - M J Dolinski
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - J Echevers
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - W Fairbank
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - D Fairbank
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - J Farine
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - S Feyzbakhsh
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - P Fierlinger
- Technische Universität München, Physikdepartment and Excellence Cluster Universe, Garching 80805, Germany
| | - D Fudenberg
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - P Gautam
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - R Gornea
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - G Gratta
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - C Hall
- Physics Department, University of Maryland, College Park, Maryland 20742, USA
| | - E V Hansen
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - J Hoessl
- Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - P Hufschmidt
- Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - M Hughes
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - A Iverson
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - A Jamil
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06511, USA
| | - C Jessiman
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - M J Jewell
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - A Johnson
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A Karelin
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute", Moscow 117218, Russia
| | - L J Kaufman
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - T Koffas
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - J Kostensalo
- University of Jyväskylä, Department of Physics, P.O. Box 35 (YFL), Jyväskylä FI-40014, Finland
| | - R Krücken
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A Kuchenkov
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute", Moscow 117218, Russia
| | - K S Kumar
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - Y Lan
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A Larson
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - B G Lenardo
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - D S Leonard
- IBS Center for Underground Physics, Daejeon 34126, Korea
| | - G S Li
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - S Li
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - Z Li
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06511, USA
| | - C Licciardi
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - Y H Lin
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - R MacLellan
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - T McElroy
- Physics Department, McGill University, Montreal, Quebec H3A 2T8, Canada
| | - T Michel
- Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - B Mong
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - D C Moore
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06511, USA
| | - K Murray
- Physics Department, McGill University, Montreal, Quebec H3A 2T8, Canada
| | - P Nakarmi
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - O Njoya
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794, USA
| | - O Nusair
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - A Odian
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - I Ostrovskiy
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - A Piepke
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - A Pocar
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - F Retière
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A L Robinson
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - P C Rowson
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - D Ruddell
- Department of Physics and Physical Oceanography, University of North Carolina at Wilmington, Wilmington, North Carolina 28403, USA
| | - J Runge
- Department of Physics, Duke University, and Triangle Universities Nuclear Laboratory (TUNL), Durham, North Carolina 27708, USA
| | - S Schmidt
- Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - D Sinclair
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - K Skarpaas
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A K Soma
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - V Stekhanov
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute", Moscow 117218, Russia
| | - J Suhonen
- University of Jyväskylä, Department of Physics, P.O. Box 35 (YFL), Jyväskylä FI-40014, Finland
| | - M Tarka
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - S Thibado
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - J Todd
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - T Tolba
- Institute of High Energy Physics, Beijing 100049, China
| | - T I Totev
- Physics Department, McGill University, Montreal, Quebec H3A 2T8, Canada
| | - R Tsang
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - B Veenstra
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - V Veeraraghavan
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - P Vogel
- Kellogg Lab, Caltech, Pasadena, California 91125, USA
| | - J-L Vuilleumier
- LHEP, Albert Einstein Center, University of Bern, Bern CH-3012, Switzerland
| | - M Wagenpfeil
- Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - J Watkins
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - M Weber
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - L J Wen
- Institute of High Energy Physics, Beijing 100049, China
| | - U Wichoski
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - G Wrede
- Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - S X Wu
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - Q Xia
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06511, USA
| | - D R Yahne
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - Y-R Yen
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - O Ya Zeldovich
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute", Moscow 117218, Russia
| | - T Ziegler
- Erlangen Centre for Astroparticle Physics (ECAP), Friedrich-Alexander University Erlangen-Nürnberg, Erlangen 91058, Germany
| |
Collapse
|
31
|
Alam H, Tang M, Maitituoheti M, Dhar SS, Kumar M, Han CY, Ambati CR, Amin SB, Gu B, Chen TY, Lin YH, Chen J, Muller FL, Putluri N, Flores ER, DeMayo FJ, Baseler L, Rai K, Lee MG. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell 2020; 37:599-617.e7. [PMID: 32243837 PMCID: PMC7178078 DOI: 10.1016/j.ccell.2020.03.005] [Citation(s) in RCA: 117] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 11/08/2019] [Accepted: 03/04/2020] [Indexed: 12/19/2022]
Abstract
Epigenetic modifiers frequently harbor loss-of-function mutations in lung cancer, but their tumor-suppressive roles are poorly characterized. Histone methyltransferase KMT2D (a COMPASS-like enzyme, also called MLL4) is among the most highly inactivated epigenetic modifiers in lung cancer. Here, we show that lung-specific loss of Kmt2d promotes lung tumorigenesis in mice and upregulates pro-tumorigenic programs, including glycolysis. Pharmacological inhibition of glycolysis preferentially impedes tumorigenicity of human lung cancer cells bearing KMT2D-inactivating mutations. Mechanistically, Kmt2d loss widely impairs epigenomic signals for super-enhancers/enhancers, including the super-enhancer for the circadian rhythm repressor Per2. Loss of Kmt2d decreases expression of PER2, which regulates multiple glycolytic genes. These findings indicate that KMT2D is a lung tumor suppressor and that KMT2D deficiency confers a therapeutic vulnerability to glycolytic inhibitors.
Collapse
Affiliation(s)
- Hunain Alam
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Ming Tang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX 77054, USA
| | - Mayinuer Maitituoheti
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX 77054, USA
| | - Shilpa S Dhar
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Manish Kumar
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Chae Young Han
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Chandrashekar R Ambati
- Advanced Technology Core and Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Samir B Amin
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX 77054, USA
| | - Bingnan Gu
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Tsai-Yu Chen
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Yu-Hsi Lin
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, TX 77054, USA
| | - Jichao Chen
- Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Florian L Muller
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, TX 77054, USA
| | - Nagireddy Putluri
- Advanced Technology Core and Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Elsa R Flores
- Department of Molecular Oncology and Cancer Biology and Evolution Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
| | - Francesco J DeMayo
- Reproductive and Developmental Biology Laboratory, The National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA
| | - Laura Baseler
- Department of Veterinary Medicine & Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Kunal Rai
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX 77054, USA.
| | - Min Gyu Lee
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
| |
Collapse
|
32
|
Zhou Q, Lin S, Lin YH, Zhu YY. [Expression of serum IgG4 in patients with non-IgG4-related hepatobiliary diseases]. Zhonghua Gan Zang Bing Za Zhi 2020; 28:152-154. [PMID: 32164067 DOI: 10.3760/cma.j.issn.1007-3418.2020.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Q Zhou
- Liver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
| | | | | | | |
Collapse
|
33
|
Anton G, Badhrees I, Barbeau PS, Beck D, Belov V, Bhatta T, Breidenbach M, Brunner T, Cao GF, Cen WR, Chambers C, Cleveland B, Coon M, Craycraft A, Daniels T, Danilov M, Darroch L, Daugherty SJ, Davis J, Delaquis S, Der Mesrobian-Kabakian A, DeVoe R, Dilling J, Dolgolenko A, Dolinski MJ, Echevers J, Fairbank W, Fairbank D, Farine J, Feyzbakhsh S, Fierlinger P, Fudenberg D, Gautam P, Gornea R, Gratta G, Hall C, Hansen EV, Hoessl J, Hufschmidt P, Hughes M, Iverson A, Jamil A, Jessiman C, Jewell MJ, Johnson A, Karelin A, Kaufman LJ, Koffas T, Krücken R, Kuchenkov A, Kumar KS, Lan Y, Larson A, Lenardo BG, Leonard DS, Li GS, Li S, Li Z, Licciardi C, Lin YH, MacLellan R, McElroy T, Michel T, Mong B, Moore DC, Murray K, Njoya O, Nusair O, Odian A, Ostrovskiy I, Piepke A, Pocar A, Retière F, Robinson AL, Rowson PC, Ruddell D, Runge J, Schmidt S, Sinclair D, Soma AK, Stekhanov V, Tarka M, Todd J, Tolba T, Totev TI, Veenstra B, Veeraraghavan V, Vogel P, Vuilleumier JL, Wagenpfeil M, Watkins J, Weber M, Wen LJ, Wichoski U, Wrede G, Wu SX, Xia Q, Yahne DR, Yang L, Yen YR, Zeldovich OY, Ziegler T. Search for Neutrinoless Double-β Decay with the Complete EXO-200 Dataset. Phys Rev Lett 2019; 123:161802. [PMID: 31702371 DOI: 10.1103/physrevlett.123.161802] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Revised: 07/30/2019] [Indexed: 06/10/2023]
Abstract
A search for neutrinoless double-β decay (0νββ) in ^{136}Xe is performed with the full EXO-200 dataset using a deep neural network to discriminate between 0νββ and background events. Relative to previous analyses, the signal detection efficiency has been raised from 80.8% to 96.4±3.0%, and the energy resolution of the detector at the Q value of ^{136}Xe 0νββ has been improved from σ/E=1.23% to 1.15±0.02% with the upgraded detector. Accounting for the new data, the median 90% confidence level 0νββ half-life sensitivity for this analysis is 5.0×10^{25} yr with a total ^{136}Xe exposure of 234.1 kg yr. No statistically significant evidence for 0νββ is observed, leading to a lower limit on the 0νββ half-life of 3.5×10^{25} yr at the 90% confidence level.
Collapse
Affiliation(s)
- G Anton
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - I Badhrees
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - P S Barbeau
- Department of Physics, Duke University, and Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - D Beck
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - V Belov
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Center "Kurchatov Institute," 117218 Moscow, Russia
| | - T Bhatta
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - M Breidenbach
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - T Brunner
- Physics Department, McGill University, Montreal H3A 2T8, Quebec, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - G F Cao
- Institute of High Energy Physics, Beijing 100049, China
| | - W R Cen
- Institute of High Energy Physics, Beijing 100049, China
| | - C Chambers
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - B Cleveland
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - M Coon
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - A Craycraft
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - T Daniels
- Department of Physics and Physical Oceanography, University of North Carolina at Wilmington, Wilmington, North Carolina 28403, USA
| | - M Danilov
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Center "Kurchatov Institute," 117218 Moscow, Russia
| | - L Darroch
- Physics Department, McGill University, Montreal H3A 2T8, Quebec, Canada
| | - S J Daugherty
- Physics Department and CEEM, Indiana University, Bloomington, Indiana 47405, USA
| | - J Davis
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - S Delaquis
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | | | - R DeVoe
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - J Dilling
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A Dolgolenko
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Center "Kurchatov Institute," 117218 Moscow, Russia
| | - M J Dolinski
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - J Echevers
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - W Fairbank
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - D Fairbank
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - J Farine
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - S Feyzbakhsh
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - P Fierlinger
- Physik Department and Excellence Cluster Universe, Technische Universität München, Garching 80805, Germany
| | - D Fudenberg
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - P Gautam
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - R Gornea
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - G Gratta
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - C Hall
- Physics Department, University of Maryland, College Park, Maryland 20742, USA
| | - E V Hansen
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - J Hoessl
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - P Hufschmidt
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - M Hughes
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - A Iverson
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - A Jamil
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06511, USA
| | - C Jessiman
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - M J Jewell
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - A Johnson
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A Karelin
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Center "Kurchatov Institute," 117218 Moscow, Russia
| | - L J Kaufman
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - T Koffas
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - R Krücken
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A Kuchenkov
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Center "Kurchatov Institute," 117218 Moscow, Russia
| | - K S Kumar
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794, USA
| | - Y Lan
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A Larson
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - B G Lenardo
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - D S Leonard
- IBS Center for Underground Physics, Daejeon 34126, Korea
| | - G S Li
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - S Li
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - Z Li
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06511, USA
| | - C Licciardi
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - Y H Lin
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - R MacLellan
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - T McElroy
- Physics Department, McGill University, Montreal H3A 2T8, Quebec, Canada
| | - T Michel
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - B Mong
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - D C Moore
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06511, USA
| | - K Murray
- Physics Department, McGill University, Montreal H3A 2T8, Quebec, Canada
| | - O Njoya
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794, USA
| | - O Nusair
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - A Odian
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - I Ostrovskiy
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - A Piepke
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - A Pocar
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - F Retière
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A L Robinson
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - P C Rowson
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - D Ruddell
- Department of Physics and Physical Oceanography, University of North Carolina at Wilmington, Wilmington, North Carolina 28403, USA
| | - J Runge
- Department of Physics, Duke University, and Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - S Schmidt
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - D Sinclair
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - A K Soma
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - V Stekhanov
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Center "Kurchatov Institute," 117218 Moscow, Russia
| | - M Tarka
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - J Todd
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - T Tolba
- Institute of High Energy Physics, Beijing 100049, China
| | - T I Totev
- Physics Department, McGill University, Montreal H3A 2T8, Quebec, Canada
| | - B Veenstra
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - V Veeraraghavan
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - P Vogel
- Kellogg Lab, Caltech, Pasadena, California 91125, USA
| | - J-L Vuilleumier
- LHEP, Albert Einstein Center, University of Bern, Bern CH-3012, Switzerland
| | - M Wagenpfeil
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - J Watkins
- Physics Department, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - M Weber
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - L J Wen
- Institute of High Energy Physics, Beijing 100049, China
| | - U Wichoski
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - G Wrede
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91058, Germany
| | - S X Wu
- Physics Department, Stanford University, Stanford, California 94305, USA
| | - Q Xia
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06511, USA
| | - D R Yahne
- Physics Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - L Yang
- Physics Department, University of Illinois, Urbana-Champaign, Illinois 61801, USA
| | - Y-R Yen
- Department of Physics, Drexel University, Philadelphia, Pennsylvania 19104, USA
| | - O Ya Zeldovich
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Center "Kurchatov Institute," 117218 Moscow, Russia
| | - T Ziegler
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91058, Germany
| |
Collapse
|
34
|
Amenomori M, Bao YW, Bi XJ, Chen D, Chen TL, Chen WY, Chen X, Chen Y, Cui SW, Ding LK, Fang JH, Fang K, Feng CF, Feng Z, Feng ZY, Gao Q, Gou QB, Guo YQ, He HH, He ZT, Hibino K, Hotta N, Hu H, Hu HB, Huang J, Jia HY, Jiang L, Jin HB, Kajino F, Kasahara K, Katayose Y, Kato C, Kato S, Kawata K, Kozai M, Le GM, Li AF, Li HJ, Li WJ, Lin YH, Liu B, Liu C, Liu JS, Liu MY, Lou YQ, Lu H, Meng XR, Mitsui H, Munakata K, Nakamura Y, Nanjo H, Nishizawa M, Ohnishi M, Ohta I, Ozawa S, Qian XL, Qu XB, Saito T, Sakata M, Sako TK, Sengoku Y, Shao J, Shibata M, Shiomi A, Sugimoto H, Takita M, Tan YH, Tateyama N, Torii S, Tsuchiya H, Udo S, Wang H, Wu HR, Xue L, Yagisawa K, Yamamoto Y, Yang Z, Yuan AF, Zhai LM, Zhang HM, Zhang JL, Zhang X, Zhang XY, Zhang Y, Zhang Y, Zhang Y, Zhou XX. First Detection of Photons with Energy beyond 100 TeV from an Astrophysical Source. Phys Rev Lett 2019; 123:051101. [PMID: 31491288 DOI: 10.1103/physrevlett.123.051101] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 05/21/2019] [Indexed: 06/10/2023]
Abstract
We report on the highest energy photons from the Crab Nebula observed by the Tibet air shower array with the underground water-Cherenkov-type muon detector array. Based on the criterion of a muon number measured in an air shower, we successfully suppress 99.92% of the cosmic-ray background events with energies E>100 TeV. As a result, we observed 24 photonlike events with E>100 TeV against 5.5 background events, which corresponds to a 5.6σ statistical significance. This is the first detection of photons with E>100 TeV from an astrophysical source.
Collapse
Affiliation(s)
- M Amenomori
- Department of Physics, Hirosaki University, Hirosaki 036-8561, Japan
| | - Y W Bao
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - X J Bi
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - D Chen
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - T L Chen
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - W Y Chen
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Xu Chen
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - Y Chen
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - S W Cui
- Department of Physics, Hebei Normal University, Shijiazhuang 050016, China
| | - L K Ding
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J H Fang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - K Fang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - C F Feng
- Department of Physics, Shandong University, Jinan 250100, China
| | - Zhaoyang Feng
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Z Y Feng
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - Qi Gao
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - Q B Gou
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Y Q Guo
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H H He
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Z T He
- Department of Physics, Hebei Normal University, Shijiazhuang 050016, China
| | - K Hibino
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - N Hotta
- Faculty of Education, Utsunomiya University, Utsunomiya 321-8505, Japan
| | - Haibing Hu
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - H B Hu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J Huang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H Y Jia
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - L Jiang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H B Jin
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - F Kajino
- Department of Physics, Konan University, Kobe 658-8501, Japan
| | - K Kasahara
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan
| | - Y Katayose
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - C Kato
- Department of Physics, Shinshu University, Matsumoto 390-8621, Japan
| | - S Kato
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - K Kawata
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - M Kozai
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara 252-5210, Japan
| | - G M Le
- National Center for Space Weather, China Meteorological Administration, Beijing 100081, China
| | - A F Li
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Department of Physics, Shandong University, Jinan 250100, China
- School of Information Science and Engineering, Shandong Agriculture University, Taian 271018, China
| | - H J Li
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - W J Li
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| | - Y H Lin
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - B Liu
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - C Liu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J S Liu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - M Y Liu
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - Y-Q Lou
- Physics Department, Astronomy Department and Tsinghua Center for Astrophysics, Tsinghua-National Astronomical Observatories of China joint Research Center for Astrophysics, Tsinghua University, Beijing 100084, China
| | - H Lu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X R Meng
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - H Mitsui
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - K Munakata
- Department of Physics, Shinshu University, Matsumoto 390-8621, Japan
| | - Y Nakamura
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H Nanjo
- Department of Physics, Hirosaki University, Hirosaki 036-8561, Japan
| | - M Nishizawa
- National Institute of Informatics, Tokyo 101-8430, Japan
| | - M Ohnishi
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - I Ohta
- Sakushin Gakuin University, Utsunomiya 321-3295, Japan
| | - S Ozawa
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan
| | - X L Qian
- Department of Mechanical and Electrical Engineering, Shandong Management University, Jinan 250357, China
| | - X B Qu
- College of Science, China University of Petroleum, Qingdao, 266555, China
| | - T Saito
- Tokyo Metropolitan College of Industrial Technology, Tokyo 116-8523, Japan
| | - M Sakata
- Department of Physics, Konan University, Kobe 658-8501, Japan
| | - T K Sako
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - Y Sengoku
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - J Shao
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- Department of Physics, Shandong University, Jinan 250100, China
| | - M Shibata
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - A Shiomi
- College of Industrial Technology, Nihon University, Narashino 275-8576, Japan
| | - H Sugimoto
- Shonan Institute of Technology, Fujisawa 251-8511, Japan
| | - M Takita
- Institute for Cosmic Ray Research, University of Tokyo, Kashiwa 277-8582, Japan
| | - Y H Tan
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - N Tateyama
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - S Torii
- Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan
| | - H Tsuchiya
- Japan Atomic Energy Agency, Tokai-mura 319-1195, Japan
| | - S Udo
- Faculty of Engineering, Kanagawa University, Yokohama 221-8686, Japan
| | - H Wang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - H R Wu
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - L Xue
- Department of Physics, Shandong University, Jinan 250100, China
| | - K Yagisawa
- Faculty of Engineering, Yokohama National University, Yokohama 240-8501, Japan
| | - Y Yamamoto
- Department of Physics, Konan University, Kobe 658-8501, Japan
| | - Z Yang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - A F Yuan
- Physics Department of Science School, Tibet University, Lhasa 850000, China
| | - L M Zhai
- National Astronomical Observatories, Chinese Academy of Sciences, Beijing 100012, China
| | - H M Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - J L Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X Zhang
- School of Astronomy and Space Science, Nanjing University, Nanjing 210093, China
| | - X Y Zhang
- Department of Physics, Shandong University, Jinan 250100, China
| | - Y Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Yi Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Ying Zhang
- Key Laboratory of Particle Astrophysics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - X X Zhou
- Institute of Modern Physics, SouthWest Jiaotong University, Chengdu 610031, China
| |
Collapse
|
35
|
Pisaneschi F, Lin YH, Leonard PG, Satani N, Yan VC, Hammoudi N, Raghavan S, Link TM, K Georgiou D, Czako B, Muller FL. The 3 S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues. Molecules 2019; 24:molecules24132510. [PMID: 31324042 PMCID: PMC6651268 DOI: 10.3390/molecules24132510] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 06/25/2019] [Accepted: 07/04/2019] [Indexed: 02/01/2023] Open
Abstract
We recently reported that SF2312 ((1,5-dihydroxy-2-oxopyrrolidin-3-yl)phosphonic acid), a phosphonate antibiotic with a previously unknown mode of action, is a potent inhibitor of the glycolytic enzyme, Enolase. SF2312 can only be synthesized as a racemic-diastereomeric mixture. However, co-crystal structures with Enolase 2 (ENO2) have consistently shown that only the (3S,5S)-enantiomer binds to the active site. The acidity of the alpha proton at C-3, which deprotonates under mildly alkaline conditions, results in racemization; thus while the separation of four enantiomeric intermediates was achieved via chiral High Performance Liquid Chromatography (HPLC) of the fully protected intermediate, deprotection inevitably nullified enantiopurity. To prevent epimerization of the C-3, we designed and synthesized MethylSF2312, ((1,5-dihydroxy-3-methyl-2-oxopyrrolidin-3-yl)phosphonic acid), which contains a fully-substituted C-3 alpha carbon. As a racemic-diastereomeric mixture, MethylSF2312 is equipotent to SF2312 in enzymatic and cellular systems against Enolase. Chiral HPLC separation of a protected MethylSF2312 precursor resulted in the efficient separation of the four enantiomers. After deprotection and inevitable re-equilibration of the anomeric C-5, (3S)-MethylSF2312 was up to 2000-fold more potent than (3R)-MethylSF2312 in an isolated enzymatic assay. This observation strongly correlates with biological activity in both human cancer cells and bacteria for the 3S enantiomer of SF2312. Novel X-ray structures of human ENO2 with chiral and racemic MethylSF2312 show that only (3S,5S)-enantiomer occupies the active site. Enolase inhibition is thus a direct result of binding by the (3S,5S)-enantiomer of MethylSF2312. Concurrent with these results for MethylSF2312, we contend that the (3S,5S)-SF2312 is the single active enantiomer of inhibitor SF2312.
Collapse
Affiliation(s)
- Federica Pisaneschi
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
| | - Yu-Hsi Lin
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Paul G Leonard
- Institute of Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
- Core for Biomolecular Structure and Function, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Nikunj Satani
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Victoria C Yan
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Naima Hammoudi
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Sudhir Raghavan
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Todd M Link
- Core for Biomolecular Structure and Function, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Dimitra K Georgiou
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Barbara Czako
- Institute of Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Florian L Muller
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
| |
Collapse
|
36
|
Lin YH, Lin S, Zhou Q, Wang MF, Zhu YY. [Correlation between interleukin-6 single nucleotide polymorphism and the occurrence and prognosis of hepatitis B virus-associated acute-on-chronic liver failure]. Zhonghua Gan Zang Bing Za Zhi 2019; 27:250-255. [PMID: 31082334 DOI: 10.3760/cma.j.issn.1007-3418.2019.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the correlation between interleukin-6 (IL-6) single nucleotide polymorphism (SNP) and the occurrence and prognosis of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Methods: Patients with chronic hepatic diseases diagnosed as HBV infection in the Hepatology Center of the First Affiliated Hospital of Fujian Medical University from July 2012 to March 2018 were divided into HBV-ACLF and non-ACLF group. SNP genotyping of eight loci in IL-6 gene (rs1524107, rs1800795, rs1800797, rs2069827, rs2069830, rs2069837, rs2069840 and rs2069845) was determined by the improved multi-temperature ligase detection reaction (imLDRTM) technique. Simultaneously, case data were reviewed with the 3-months followed up survival condition of the ACLF group. Normally distributed data were expressed as arithmetic means and SDs, and t-test was adopted. Data with skewed distribution were expressed as medians with interquartile range, and were measured by non-parametric test. Multivariate logistic regression analysis was used to analyze the relative risk of genetic polymorphism and HBV-ACLF as well as the relationship between IL-6 SNPs with the occurrence and prognosis of HBV-ACLF. Results: Four hundred patients were included in the study, with 122 (30.5%) in the HBV-ACLF and 278 (69.5%) in the non-ACLF group. There were significant differences in total bilirubin, albumin, and white blood cell count, percentage of neutrophils, platelet count, alanine aminotransferase, aspartate aminotransferase, prothrombin time and international standardized ratio, creatinine and the model for end-stage liver disease score between the two groups (P < 0.001). The genotype of IL-6 genes (rs1800795, rs1800797, rs2069827, and rs2069830) of all subjects showed no mutation or the mutation rate under 1%. There was no significant difference in the genotype of IL-6 (rs1524107, rs2069837, rs2069840 and rs2069845) between the two groups (P > 0.05). Multivariate logistic regression analysis showed that the SNPs in the above four loci of IL-6 gene was not associated with HBV-ACLF risk, nor had significant correlation with the 3-months prognosis. Conclusion: The SNP genotyping of eight loci in IL-6 gene (rs1524107, rs1800795, rs1800797, rs2069827, rs2069830, rs2069837, rs2069840 and rs2069845) is unrelated to the occurrence and short-term prognosis of HBV-ACLF.
Collapse
Affiliation(s)
- Y H Lin
- Liver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
| | | | | | | | | |
Collapse
|
37
|
Luo Y, Feng BF, Wei DC, Li MC, Han YL, Zhao JH, Lin YH, Li Q, Hou Z, Zhuang HY, Jiang YG. [Derepression of CXCR7 indicates resistance to enzalutamide in castration resistant prostate cancer]. Zhonghua Yi Xue Za Zhi 2019; 99:1237-1240. [PMID: 31060163 DOI: 10.3760/cma.j.issn.0376-2491.2019.16.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Objective: To investigate the effect of the derepression of chemokine receptor-7 (CXCR7) in prostatic tissues from patients with Castration Resistant Prostate Cancer (CRPC) on the resistance to enzalutamide (Enza). Methods: During the period of January 2015 to December 2017 all CRPC cases who underwent radical radiotherapy or androgen deprivation therapy (ADT) were evaluated. After prostatic puncture biopsy, the tissues were treated for immunostaining with CXCR7. Cox proportional hazard modeling and Kaplan-Meier analysis were used to determine PSA Progression-Free Survival (PSAP-FS) and Clinical or Radiographic Progression-Free Survival (CRP-FS) in the cohort. At last, PSA response rates and progression outcomes in CXCR7 negative cases and CXCR7 positive cases were analyzed. Results: Total 39 CRPC patients were enrolled in this study. And 23 cases derepress CXCR7, 16 cases negatively express CXCR7. The median follow-up duration was 12 months (range: 6-18) in the cohort. Chi-square analysis confirmed that PSA response rates after Enza treatment were significantly associated with CXCR7 derepression (χ(2)=22.129, P=0.000 06). Compared with CXCR7 positive expression group, CXCR7 negative expression group displayed improved median PSAP-FS (4.4 mon vs 11.7 mon, P=0.040 8) and CRP-FS (5.2 mon vs 13.1 mon, P=0.036 2) after Enza treatment. Conclusion: Derepression of CXCR7 in CRPC patients may be associated with resistance to enzalutamide. This protein may be novel target for treatment of CRPC.
Collapse
Affiliation(s)
- Y Luo
- Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Muller F, Hammoudi N. YIA19-004: Collateral Deletion of Glycolysis Genes Generates Selective Vulnerabilities to Inhibitors of Oxidative Phosphorylation. J Natl Compr Canc Netw 2019. [DOI: 10.6004/jnccn.2018.7219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Targeted therapies attacking specific genetic alterations in tumor cells have been an effective strategy in the treatment of many cancers and underlie the concept of “precision medicine.” Successes in various cancers have resulted almost exclusively from targeting activated oncogenes, but this approach has not been proven effective in patients with glioblastoma. We have taken a radically different approach to molecular therapy by targeting genomic deletions, which heretofore have not been considered to be therapeutically actionable. In a chemical biology drug screen of gliomas with passenger deletions in the glycolytic gene Enolase 1 (ENO1), we found that the most cytotoxic agents were those that inhibited mitochondrial oxidative phosphorylation (OxPhos), including a new drug developed at MD Anderson Cancer Center by the Institute of Applied Cancer Science (IACS), which inhibits OxPhos by binding mitochondrial complex I with nM affinity. Exquisite sensitivity to OxPhos inhibition derives from impaired glycolysis, as ENO1-deleted cells are unable to compensatory upregulate glycolysis in the face of inhibition of OxPhos, and succumb to bioenergetic failure. In addition to ENO1-deletions, we find that passenger deletion of other metabolic genes, including 6-phosphogluconate dehydrogenase (PGD), also exhibit selective sensitivity to OxPhos inhibition by the same underlying biochemical mechanism. The IACS compound was found to penetrate the blood brain-barrier and to eradicate PGD and ENO1-deleted intracranial xenografts. The lead OxPhos inhibitor, IACS-10759, is currently in phase 1 clinical trial for leukemia, and our data provide a strong rationale for advancing this agent to clinical trials in glioblastoma patients.
Collapse
Affiliation(s)
- Florian Muller
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Naima Hammoudi
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | |
Collapse
|
39
|
Luo Y, Li MC, Zhao JH, Han YL, Lin YH, Wang YX, Jiang YG, Lu Q, Lan L. [Activation of HIF-1α/β-catenin signal pathway leads to radioresistance of prostate cancer cells]. Zhonghua Yi Xue Za Zhi 2018; 98:2552-2558. [PMID: 30220138 DOI: 10.3760/cma.j.issn.0376-2491.2018.32.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the role of hypoxia-inducible factor-1α (HIF-1α) and β-catenin in radioresistance of prostate cancer (PCa) cells. Method: Two PCa cell lines, LNCaP and C4-2B, were grouped as: negative control (no treatment), HIF-1α overexpression group (transfected with HIF-1α plasmids), and β-catenin silencing group (transfected with HIF-1α plasmids and β-catenin-shRNA). Cell proliferation, cycle, invasion, and radiosensitivity were measured under normal or hypoxic condition. Radiosensitivity was tested in two mice PCa models (the LNCaP orthotopic BALB/c-nu mice model and the C4-2B subcutaneous SCID mice model). Results: In both LNCaP and C4-2B cells, HIF-1α transfection led to an enhanced β-catenin nuclear translocation, while β-catenin silencing inhibited the β-catenin nuclear translocation. Enhanced β-catenin nuclear translocation caused by HIF-1α overexpression resulted in enhanced cell proliferation and invasion, altered cell cycle distribution, reduced apoptosis, and improved non-homologous-end-joining (NHEJ) repair under irradiation condition. In vivo imaging of orthotopic models showed that HIF-1α overexpression LNCaP cells produced tumors with 3-fold volume (P=0.003 1) and 2-fold wet weight (P=0.039 4) than those by negative control cells at day 21, and β-catenin silencing cells aberrantly reduced both tumor volume (P=0.000 3) and wet weight (P=0.017 5) than HIF-1α overexpression cells. In addition, C4-2B subcutaneous models showed similar tumor promotion effects induced by HIF-1α overexpression (tumor volume: P=0.000 1 and wet weight: P=0.047 3) and suppressive effects by β-catenin silencing (tumor volume: P<0.000 1 and wet weight: P=0.022 1) as LNCaP orthotopic xenograft with regard to tumor volume and wet weight. Conclusions: HIF-1α overexpression enhanced β-catenin nuclear translocation, which led to the activation of the β-catenin/NHEJ signaling pathway and increased cell proliferation, invasion, and DNA repair. These results suggest that HIF-1α overexpression led to radioresistance of PCa cells.
Collapse
Affiliation(s)
- Y Luo
- Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Deribe YL, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Inoue A, Kochat V, Liu CG, Asara JM, Moran C, Muller F, Wang J, Fang B, Papadimitrakopoulou V, Wistuba II, Rai K, Marszalek J, Futreal PA. Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med 2018; 24:1627. [PMID: 30104769 DOI: 10.1038/s41591-018-0173-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In the version of this article originally published, information regarding several funding sources was omitted from the Acknowledgements section. The following sentences should have been included: "This work was supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program, the UT Lung SPORE 5 P50 CA07090, and the MD Anderson Cancer Center Support Grant P30CA01667. V.P is supported by R01CA155196-01A1 from the National Cancer Institute." Also, reference 18 was incorrect. The original reference was: Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011). It should have been: Papadimitrakopoulou, V. et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin. Oncol. 34, 3638-3647 (2016). The errors have been corrected in the HTML and PDF versions of this article.
Collapse
Affiliation(s)
- Yonathan Lissanu Deribe
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Yuting Sun
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Christopher Terranova
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Fatima Khan
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Juan Martinez-Ledesma
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason Gay
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Guang Gao
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Robert A Mullinax
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tin Khor
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ningping Feng
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yu-Hsi Lin
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chia-Chin Wu
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Claudia Reyes
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Qian Peng
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Frederick Robinson
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Akira Inoue
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Veena Kochat
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chang-Gong Liu
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John M Asara
- Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Cesar Moran
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Florian Muller
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jing Wang
- Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Bingliang Fang
- Department of Thoracic, Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Vali Papadimitrakopoulou
- Department of Thoracic, Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ignacio I Wistuba
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kunal Rai
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Joseph Marszalek
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - P Andrew Futreal
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
41
|
Wallner M, Eaton DM, Berretta RM, Wu J, Jeong MY, Lin YH, Baker ST, Oyama MA, Von Lewinski D, Mohsin S, McKinsey TA, Wolfson MR, Houser SR. P6505HDAC inhibition rescues cardiac and pulmonary function in a feline model of HFpEF. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Wallner
- Temple University School of Medicine, Cardiovascular Research Center, Philadelphia, United States of America
| | - D M Eaton
- Temple University School of Medicine, Cardiovascular Research Center, Philadelphia, United States of America
| | - R M Berretta
- Temple University School of Medicine, Cardiovascular Research Center, Philadelphia, United States of America
| | - J Wu
- Temple University School of Medicine, Physiology; Thoracic Medicine and Surgery; CILR, Philadelphia, United States of America
| | - M Y Jeong
- University of Colorado, Division of Cardiology and Consortium for Fibrosis Research & Translation, Aurora, United States of America
| | - Y H Lin
- University of Colorado, Division of Cardiology and Consortium for Fibrosis Research & Translation, Aurora, United States of America
| | - S T Baker
- Temple University School of Medicine, Physiology; Thoracic Medicine and Surgery; CILR, Philadelphia, United States of America
| | - M A Oyama
- University of Pennsylvania, School of Veterinary Medicine, Section of Cardiology, Philadelphia, United States of America
| | - D Von Lewinski
- Medical University of Graz, Division of Cardiology, Graz, Austria
| | - S Mohsin
- Temple University School of Medicine, Cardiovascular Research Center, Philadelphia, United States of America
| | - T A McKinsey
- University of Colorado, Division of Cardiology and Consortium for Fibrosis Research & Translation, Aurora, United States of America
| | - M R Wolfson
- Temple University School of Medicine, Physiology; Thoracic Medicine and Surgery; CILR, Philadelphia, United States of America
| | - S R Houser
- Temple University School of Medicine, Cardiovascular Research Center, Philadelphia, United States of America
| |
Collapse
|
42
|
Lin YH, Hammoudi N, Satani N, Ackroyd J, Khadka S, Georgiou D, Marszalek J, Sun Y, Protopopova M, Francesco MED, Czako B, Wang AY, DePinho RA, Muller FL. Abstract 2831: Collateral lethality: A new target for personalized oncology. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Large-scale genomic profiling efforts, such as The Cancer Genome Atlas (TCGA) have painted an unprecedentedly detailed picture of the genetic alterations that underlie carcinogenesis, yet the key challenge remains as to how to turn this information into actionable therapies. Genomic deletions are a frequent event in diverse cancers, which inactivate a limited number of tumor suppressor genes (“driver”-events) but frequently include many chromosomal neighbors as “passengers”, some of which play critical but redundant roles in normal cellular housekeeping. The overall hypothesis we propose to test is that collateral deletions of such “passenger” genes can be utilized as novel targets of synthetic lethality, an idea which we term “collateral lethality." The large number of passenger deleted genes, playing diverse functions in cell homeostasis, offers a rich repertoire of pharmacologically targetable vulnerabilities presenting novel opportunities for the development of personalized anti-neoplastic therapies. We have provided in vitro proof-of-principal of a collaterally deleted glycolytic gene Enolase 1 (ENO1) at the 1p36 tumor suppressor locus in glioblastoma (GBM), that leads to dramatic sensitization to inhibition of the redundant paralogue, ENO2. The next step is to take this concept to the clinic. Our overall goal is to generate a clinical candidate Enolase inhibitor for tumors with ENO1-deletions, like GBM for which there is no other treatment option and the therapeutic benefit could be quite substantial.
Citation Format: Yu-Hsi Lin, Naima Hammoudi, Nikunj Satani, Jeffrey Ackroyd, Sunada Khadka, Dimitra Georgiou, Joe Marszalek, Yuting Sun, Marina Protopopova, Maria E. Di Francesco, Barbara Czako, Alan Y. Wang, Ronald A. DePinho, Florian L. Muller. Collateral lethality: A new target for personalized oncology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2831.
Collapse
Affiliation(s)
- Yu-Hsi Lin
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Naima Hammoudi
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Nikunj Satani
- 2The University of Texas Health Science Center at Houston, Houston, TX
| | - Jeffrey Ackroyd
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Sunada Khadka
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Joe Marszalek
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Yuting Sun
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Barbara Czako
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Alan Y. Wang
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | |
Collapse
|
43
|
Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip ANA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med 2018; 24:1036-1046. [PMID: 29892070 DOI: 10.1038/s41591-018-0052-4] [Citation(s) in RCA: 540] [Impact Index Per Article: 90.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Accepted: 03/27/2018] [Indexed: 12/19/2022]
Abstract
Metabolic reprograming is an emerging hallmark of tumor biology and an actively pursued opportunity in discovery of oncology drugs. Extensive efforts have focused on therapeutic targeting of glycolysis, whereas drugging mitochondrial oxidative phosphorylation (OXPHOS) has remained largely unexplored, partly owing to an incomplete understanding of tumor contexts in which OXPHOS is essential. Here, we report the discovery of IACS-010759, a clinical-grade small-molecule inhibitor of complex I of the mitochondrial electron transport chain. Treatment with IACS-010759 robustly inhibited proliferation and induced apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, likely owing to a combination of energy depletion and reduced aspartate production that leads to impaired nucleotide biosynthesis. In models of brain cancer and AML, tumor growth was potently inhibited in vivo following IACS-010759 treatment at well-tolerated doses. IACS-010759 is currently being evaluated in phase 1 clinical trials in relapsed/refractory AML and solid tumors.
Collapse
Affiliation(s)
- Jennifer R Molina
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yuting Sun
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Marina Protopopova
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sonal Gera
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Madhavi Bandi
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Christopher Bristow
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Timothy McAfoos
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Pietro Morlacchi
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Agilent Technologies Inc., Lexington, MA, USA
| | - Jeffrey Ackroyd
- Department of Cancer Imaging Systems, University of Texas MD Cancer Center, Houston, TX, USA
| | - Ahmed-Noor A Agip
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK
| | - Gheath Al-Atrash
- Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John Asara
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Jennifer Bardenhagen
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Caroline C Carrillo
- Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Christopher Carroll
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Edward Chang
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Stefan Ciurea
- Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason B Cross
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Barbara Czako
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Angela Deem
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Naval Daver
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John Frederick de Groot
- Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jian-Wen Dong
- Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ningping Feng
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Guang Gao
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason Gay
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Mary Geck Do
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jennifer Greer
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Virginia Giuliani
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jing Han
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Lina Han
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Verlene K Henry
- Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Judy Hirst
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK
| | - Sha Huang
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yongying Jiang
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Zhijun Kang
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tin Khor
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sergej Konoplev
- Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yu-Hsi Lin
- Department of Cancer Imaging Systems, University of Texas MD Cancer Center, Houston, TX, USA
| | - Gang Liu
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Alessia Lodi
- Department of Nutritional Sciences, University of Texas at Austin, Austin, TX, USA
| | - Timothy Lofton
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Helen Ma
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Mikhila Mahendra
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Polina Matre
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Robert Mullinax
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michael Peoples
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Alessia Petrocchi
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jaime Rodriguez-Canale
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Riccardo Serreli
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK
| | - Thomas Shi
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Melinda Smith
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yoko Tabe
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Next Generation Hematology Laboratory Medicine, Department of Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan
| | - Jay Theroff
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Stefano Tiziani
- Department of Nutritional Sciences, University of Texas at Austin, Austin, TX, USA
| | - Quanyun Xu
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Qi Zhang
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Florian Muller
- Department of Cancer Imaging Systems, University of Texas MD Cancer Center, Houston, TX, USA
| | - Ronald A DePinho
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Carlo Toniatti
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Giulio F Draetta
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Timothy P Heffernan
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Marina Konopleva
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Philip Jones
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - M Emilia Di Francesco
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Joseph R Marszalek
- Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
44
|
Chen HG, Sheng LT, Wan ZZ, Wang XC, Lin YH, Wang YX, Pan XF, Pan A. [The relationship between smoking and hyperuricemia in Chinese residents]. Zhonghua Yu Fang Yi Xue Za Zhi 2018; 52:524-529. [PMID: 29747345 DOI: 10.3760/cma.j.issn.0253-9624.2018.05.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the relationship between smoking and hyperuricemia in Chinese residents. Methods: Based on data from the China Health and Nutrition Survey (CHNS), residents with blood samples provided in the 2009 round (including information of socio-demographic factors, lifestyle behaviors, medical history, and laboratory examinations etc.) were selected as the participants in the current analysis. Unconditional logistic regression models were utilized to compute the ORs and corresponding 95%CIs for assessing the relationship between smoking and hyperuricemia. Results: Among the 8 785 subjects, 1 435 had hyperuricemia with a prevalence rate of 16.3%, consisting of 886 men and 549 women with prevalence rates of 21.6% (886/4 110) and 11.7% (549/4 675) , respectively. Compared with never smokers, the adjusted OR (95%CI) for hyperuricemia was 0.83 (0.70-0.98) among current smokers, 0.77 (0.63-0.94) among current smokers with 20-39 years of smoking, and 0.79 (0.65-0.97) among current smokers with 11-20 cigarettes per day. When stratified by gender and compared with non-smoker, the adjusted OR (95%CI) for hyperuricemia among current smokers compared with never smokers was 0.83 (0.70-0.98) among men, while no significant association was found in female current smokers (OR=0.73, 95%CI: 0.42-1.26, P=0.260). Conclusion: In Chinese residents, there is an inverse association between smoking and hyperuricemia prevalence, and this association may be related to duration and intensity of smoking among current smokers. The findings need to be validated in large prospective cohort studies.
Collapse
Affiliation(s)
- H G Chen
- Department of Epidemiology and Biostatistics School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Inoue A, Kochat V, Liu CG, Asara JM, Moran C, Muller F, Wang J, Fang B, Papadimitrakopoulou V, Wistuba II, Rai K, Marszalek J, Futreal PA. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med 2018; 24:1047-1057. [PMID: 29892061 DOI: 10.1038/s41591-018-0019-5] [Citation(s) in RCA: 150] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Accepted: 03/20/2018] [Indexed: 01/09/2023]
Abstract
Lung cancer is a devastating disease that remains a top cause of cancer mortality. Despite improvements with targeted and immunotherapies, the majority of patients with lung cancer lack effective therapies, underscoring the need for additional treatment approaches. Genomic studies have identified frequent alterations in components of the SWI/SNF chromatin remodeling complex including SMARCA4 and ARID1A. To understand the mechanisms of tumorigenesis driven by mutations in this complex, we developed a genetically engineered mouse model of lung adenocarcinoma by ablating Smarca4 in the lung epithelium. We demonstrate that Smarca4 acts as a bona fide tumor suppressor and cooperates with p53 loss and Kras activation. Gene expression analyses revealed the signature of enhanced oxidative phosphorylation (OXPHOS) in SMARCA4 mutant tumors. We further show that SMARCA4 mutant cells have enhanced oxygen consumption and increased respiratory capacity. Importantly, SMARCA4 mutant lung cancer cell lines and xenograft tumors have marked sensitivity to inhibition of OXPHOS by a novel small molecule, IACS-010759, that is under clinical development. Mechanistically, we show that SMARCA4-deficient cells have a blunted transcriptional response to energy stress creating a therapeutically exploitable synthetic lethal interaction. These findings provide the mechanistic basis for further development of OXPHOS inhibitors as therapeutics against SWI/SNF mutant tumors.
Collapse
Affiliation(s)
- Yonathan Lissanu Deribe
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Yuting Sun
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Christopher Terranova
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Fatima Khan
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Juan Martinez-Ledesma
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason Gay
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Guang Gao
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Robert A Mullinax
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tin Khor
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ningping Feng
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yu-Hsi Lin
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chia-Chin Wu
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Claudia Reyes
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Qian Peng
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Frederick Robinson
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Akira Inoue
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Veena Kochat
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chang-Gong Liu
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John M Asara
- Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | - Cesar Moran
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Florian Muller
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jing Wang
- Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Bingliang Fang
- Department of Thoracic, Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Vali Papadimitrakopoulou
- Department of Thoracic, Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ignacio I Wistuba
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kunal Rai
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Joseph Marszalek
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - P Andrew Futreal
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
46
|
Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CEG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RG. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 2018; 33:152. [PMID: 29316430 PMCID: PMC5892424 DOI: 10.1016/j.ccell.2017.12.012] [Citation(s) in RCA: 132] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Do-Hyun Nam
- Correspondence:
(E.P.S.), (D.-H.N.),
(R.G.W.V.)
| | | |
Collapse
|
47
|
Wang Q, Hu B, Hu X, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel FP, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Olar A, Lan Z, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz K, Wang G, Eskilsson E, Hu J, Mikkelsen T, Depinho R, Muller F, Heimberger A, Sulman E, Nam DH, Verhaak R. TMIC-22. DECIPHERING GLIOMA INTRINSIC TRANSCRIPTIONAL SUBTYPES IDENTIFIES TUMOR EVOLUTION ASSOCIATES WITH CHANGES IN IMMUNE-MICROENVIRONMENT. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.1011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Lin YH, Satani N, Hammoudi N, Pisaneschi F, Leonard P, Maxwell D, Peng Z, Link T, Gilbert LIVR, Bosajou A, Sun D, Marszalek J, Sun Y, McMurray JS, Mandal PK, Francesco MED, Czako B, Wang A, Bornmann W, DePinho RA, Muller F. Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer. Mol Cancer Ther 2017. [DOI: 10.1158/1538-8514.synthleth-a39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glycolysis inhibition is an active area of investigation for the treatment of cancer. However, few compounds have progressed beyond the cell culture stage. We have recently demonstrated that genomic passenger deletion of the glycolytic enzyme Enolase 1 (ENO1) leaves gliomas harboring such deletions solely reliant on ENO2, rendering them exquisitely sensitive to enolase inhibitors Collateral Lethality. However, the tool compound that we employed for these in vitro studies, Phosphonoacetohydroxamate (PhAH), has very poor pharmacological properties and was ineffective in vivo. We recently reported that a structural analogue of PhAH, the natural phosphonate antibiotic SF2312, is a high potency inhibitor of Enolase. While more potent than PhAH, SF2312 remains poorly cell permeable. Here, we generated a Pivaloyloxymethyl (POM) ester pro-drug derivative of SF2312, termed POMSF, which increased the potency in cell based systems by ~50-fold. POMSF is selectively active against ENO1-deleted glioma cells in culture at ~19 nM, versus μM for SF2312. However, POMSF displayed poor aqueous stability. A derivative of POMSF, termed POMHEX, showed greater stability and its active form, HEX, showed 4-fold preference for ENO1 over ENO2. Labeled 13C-glucose tracing shows that POMHEX inhibits glycolysis at the Enolase step in all cell lines tested, but with ~100-fold greater potency in ENO1-deleted lines. POMHEX selectively killed ENO1-deleted glioma cells with an IC50 <30nM, whilst non-deleted cells could readily tolerate μM levels of inhibitor. As such, POMHEX was selected for in vivo experiments. Using an orthotopic intracranial xenografted model where tumor growth and response to therapy are monitored by MRI, we show that POMHEX is capable of eradicating intracranial ENO1-deleted tumors, with mice remaining recurrence-free even after treatment discontinuation. Taken together, these results reinforce that glycolysis is a viable target and provide in vivo proof-of-principal for the concept of using passenger deletions as targetable vulnerabilities in personalized cancer therapy.
Citation Format: Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, Federica Pisaneschi, Paul Leonard, David Maxwell, Zhenghong Peng, Todd Link, Lee IV R. Gilbert, Ananth Bosajou, Duoli Sun, Joe Marszalek, Yuting Sun, John S. McMurray, Pijus K. Mandal, Maria E. Di Francesco, Barbara Czako, Alan Wang, William Bornmann, Ronald A. DePinho, Florian Muller. Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr A39.
Collapse
Affiliation(s)
- Yu-Hsi Lin
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | | | - Naima Hammoudi
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | | | - Paul Leonard
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - David Maxwell
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Zhenghong Peng
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Todd Link
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | | | - Ananth Bosajou
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Duoli Sun
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Joe Marszalek
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Yuting Sun
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - John S. McMurray
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Pijus K. Mandal
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | | | - Barbara Czako
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Alan Wang
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| | | | | | - Florian Muller
- 1The University of Texas MD Anderson Cancer Center, Houston, TX,
| |
Collapse
|
49
|
Wu CC, Hsu CJ, Huang FL, Lin YH, Lin YH, Liu TC, Wu CM. Timing of cochlear implantation in auditory neuropathy patients with OTOF mutations: Our experience with 10 patients. Clin Otolaryngol 2017; 43:352-357. [PMID: 28766844 DOI: 10.1111/coa.12949] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/19/2017] [Indexed: 11/27/2022]
Affiliation(s)
- C C Wu
- Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan
| | - C J Hsu
- Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.,Department of Otolaryngology, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan
| | - F L Huang
- Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan
| | - Y H Lin
- Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.,Graduate Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Y H Lin
- Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.,Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan
| | - T C Liu
- Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan
| | - C M Wu
- Department of Otolaryngology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan
| |
Collapse
|
50
|
Luo Y, Li MC, Qi HZ, Zhao JH, Han YL, Lin YH, Hou Z, Jiang YG. [Long-term oncologic outcomes of localized high-risk prostate cancer undergoing brachytherapy combined with external-beam radiation therapy and maximal androgen blockade]. Zhonghua Yi Xue Za Zhi 2017; 97:2028-2032. [PMID: 28763873 DOI: 10.3760/cma.j.issn.0376-2491.2017.26.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Objective: To investigate the oncologic outcome and PSA kinetics of localized high-risk prostate cancer (PCa) patients treated with combination strategy of radiation therapy (RT) and maximal androgen blockade (MAB). Methods: We retrospectively reviewed the clinical data of 320 localized PCa patients undergoing RT+ MAB from 2001 to 2015. And radiation treatment protocol consisted of permanent prostate brachytherapy (PPB) at 110 Gy and EBRT at 45 Gy/23 fractions. Results: The median follow-up time was 90 (range: 12-186) months. And 117 (36.6%) cases underwent MAB + external-beam radiotherapy (EBRT), and other 203 (63.4%) cases received MAB+ EBRT+ PPB. Multivariate Cox regression analyses showed that PSA kinetics were positive indicators of oncologic outcomes. Furthermore, PSA kinetics were aberrantly improved by supplemental PPB to MAB+ EBRT as following, PSA nadir (1.3±0.7)μg/L vs(0.11±0.06)μg/L, time of PSA decrease to nadir (7.5±1.8)months vs (3.2±2.1)months, PSA doubling time (15.6±4.2)months vs (22.6±6.1)months, PSA decreasing amplitude (84.6±6.2)%vs(95.8±3.4)%. Additionally, the median time of several important oncologic events in MAB+ EBRT+ PPB group were also prolonged than that in MAB+ EBRT group as following, overall survival (12.3 years vs 9.1 years, P<0.001), biochemical recurrence-free survival (9.8 years vs 6.5 years, P<0.001), skeletal-related event (10.4years vs 8.2 years, P<0.001), and cytotoxic chemotherapy (11.6 years vs 8.8 years, P=0.007). Conclusion: MAB+ EBRT+ PPB is extremely effective combination strategy for localized high-risk PCa patients, and PPB plays the important synergistic role in improving PSA kinetics, which are independent predictor for oncologic outcomes.
Collapse
Affiliation(s)
- Y Luo
- Department of Urology, Affiliated Beijing Anzhen hospital of Capital Medical University, Beijing 100029, China
| | | | | | | | | | | | | | | |
Collapse
|